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Abstract 
The availability of a huge range of drugs for treating various diseases has become normal in our current 
daily life. However, the process behind the development of new drugs still holds many challenges. As 
antibiotic resistance increases, new drugs must continuously be developed, and many illnesses still 
lack suitable medical cures, particularly neglected tropical diseases and genetic conditions. This thesis 
covers the structural characterisation and inhibitor screening of two important targets related to 
infectious diseases: the antibiotic-resistance protein IMP-13 and the trypanosomal PEX14 protein, 
implicated in the neglected tropical disease, Chagas Disease. The challenges in drug discovery are 
many-fold, and some of these are highlighted and addressed in this thesis, along with methodological 
developments to overcome them. 
Metallo-β-lactamases lead to antibiotic resistance in a range of bacterial pathogens that both affect 
humans and act as natural reservoirs in soil and animals. They render current antibiotics of last resort, 
the carbapenems, useless, whilst being co-expressed with other resistance factors. Fragment-based 
drug discovery is an efficient process for the rational development of small molecule inhibitors. NMR 
fragment screens readily identify hits but these ligands are often are not visible in crystallographic 
structures. To get around this problem, the metallo-β-lactamase target IMP-13 was crystallised with 
its natural substrates, the carbapenems. Subsequent structure determination highlighted key 
interactions and the recognition of the ligand by the protein, enabling further work to deduce the 
mode of binding of the fragments. It also suggested a new screening principle, which has since led to 
the discovery of fragments that stabilise a specific protein conformation and yielded further 
crystallographic structures. 
PEX14 is a peroxisomal membrane-associated protein with an N-terminal domain that forms protein-
protein interactions with the cargo receptor PEX5. PEX5 binds to cargo proteins that are, through the 
PEX14-PEX5 interactions, translocated into the peroxisomal lumen. PEX14 has been shown to be 
essential for survival of Trypanosoma parasites, such as T. brucei, which causes African Sleeping 
Sickness. Structural studies of PEX14 of T. cruzi, which causes Chagas Disease remained elusive, 
despite the high medical need for Chagas therapy and its promising role in drug discovery. The crystal 
structure of T. cruzi PEX14 N-terminal domain is presented along with solution-state NMR 
assignments. NMR fragment screening experiments were applied to identify starting points for 
inhibitor design. However, difficulties in obtaining structural information on fragment-protein 
complexes using standard crystallographic and NMR techniques led to investigation of the utility of 
paramagnetic NMR to characterise ligand poses. 
A review of the current methods and applications of paramagnetic NMR in drug discovery is 
presented. Various methods for conjugating paramagnetic lanthanide binding tags were studied and 
the utility of structural information from pseudocontact shift and paramagnetic relaxation 
enhancements for structural analysis of PEX14-ligand complexes is assessed. Lanthanide tags were 
applied to PEX14 and a cysteine mutant and measured to gain restraints for modelling binding poses 
of fragments. 
Water molecules are known to play an important role in binding properties of protein-ligand 
complexes, as well as the dynamics and folding of proteins themselves, giving valuable information 
for drug discovery. Whilst high-resolution crystal structures give information on water molecule 
placement, this is lacking from low-resolution crystal structures, NMR and cryo-EM. A deep learning 
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algorithm has been trained on high-resolution crystal structures and predict positions of water 
molecules on NMR and cryo-EM structures. The approach has been validated with experimental 
structures of IMP-13 and the T. cruzi PEX14 N-terminal domain. 
The results presented in this thesis provide novel insight and methodology to address current 
challenges in early stage drug discovery, and are readily applicable to many systems. 
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Zusammenfassung 
Die Verfügbarkeit von Medikamenten zur Behandlung verschiedener Krankheiten ist in westlichen 
Gesundheitssystemen zur Normalität geworden. Allerdings birgt der Prozess der 
Medikamentenentwicklung viele Herausforderungen. Da die Antibiotikaresistenz zunimmt, müssen 
ständig neue Medikamente entwickelt werden, und bei vielen Krankheiten fehlt es noch immer an 
geeigneten Wirkstoffen, insbesondere bei vernachlässigten Tropenkrankheiten und genetischen 
Erkrankungen. Diese Arbeit befasst sich mit der strukturellen Charakterisierung und dem Inhibitor-
Screening von zwei wichtigen Targets im Zusammenhang mit Infektionskrankheiten: IMP-13, einem 
Antibiotikaresistenzprotein und PEX14, einem trypanosomalen Protein, das bei der vernachlässigten 
Tropenkrankheit Chagas-Krankheit eine Rolle spielt. Die Herausforderungen in der 
Wirkstoffentwicklung sind vielfältig, und einige davon werden in dieser Arbeit hervorgehoben und 
angesprochen, zusammen mit methodischen Entwicklungen zu ihrer Bewältigung. 
Metallo-β-Laktamasen führen zu Antibiotikaresistenzen bei einer Reihe von bakteriellen 
Krankheitserregern, die sowohl den Menschen betreffen als auch als natürliche Reservoirs in Boden 
und Tieren wirken. Sie machen die derzeitigen Antibiotika der letzten Instanz, die Carbapeneme, 
wirkungslos, und sie werden mit anderen Resistenzfaktoren koexprimiert. Die fragmentbasierte 
Arzneimittelentwicklung ist eine effiziente Methode für die rationale Entwicklung von Inhibitoren. 
Durch Fragmentscreens mittels Kernspinresonanz Spektroskopie lassen sich Treffer leicht 
identifizieren, aber diese Liganden sind in Kristallstrukturen oft nicht sichtbar. Um dieses Problem zu 
umgehen, wurde das Metallo-β-Lactamase IMP-13 mit seinen natürlichen Substraten, den 
Carbapenemen, kristallisiert. Bei der anschließenden Strukturbestimmung wurden 
Schlüsselinteraktionen und die Erkennung der Liganden durch das Protein hervorgehoben, so dass 
weitere Arbeit zur Ableitung des Bindungsmodus der Fragmente möglich waren. Sie schlug auch ein 
neues Screening-Prinzip vor, das seither zur Entdeckung von Fragmenten geführt hat, die eine 
bestimmte Proteinkonformation stabilisieren und weitere Kristallstrukturen hervorbrachten. 
PEX14 ist ein peroxisomales, membranassoziiertes Protein mit einer N-terminalen Domäne, die 
Protein-Protein-Interaktionen mit dem Cargo-Rezeptor PEX5 bildet. PEX5 bindet an Cargo-Proteine, 
die in Abhängigkeit von der PEX14-PEX5-Interaktion in das peroxisomale Lumen transloziert werden. 
Es hat sich gezeigt, dass PEX14 für das Überleben von Trypanosoma-Parasiten, wie z.B. T. brucei, dem 
Erreger der Afrikanischen Schlafkrankheit, von entscheidender Bedeutung ist. Strukturelle Studien zu 
PEX14 von T. cruzi, dem Erreger der Chagas-Krankheit, blieben trotz des hohen medizinischen Bedarfs 
für eine Chagas-Therapie und ihrer vielversprechenden Rolle bei der Entdeckung von Medikamenten 
schwer zugänglich. Die Kristallstruktur der N-terminalen Domäne von PEX14 von T. cruzi und eine 
Zuordnung der NMR Signale werden hier vorgestellt. NMR-Fragmentscreening-Experimente wurden 
angewandt, um Ausgangspunkte für die Inhibitorenentwicklung zu identifizieren. Schwierigkeiten bei 
der Gewinnung struktureller Informationen über Fragment-Proteinkomplexe mit Hilfe von oft 
benutzten Kristallographie- und NMR-Techniken führten zur Untersuchung von paramagnetischen 
NMR Experimenten zur Charakterisierung der Ligandenpositionen. 
Ein Übersichtsartikel beschreibt aktuelle Methoden und Anwendungen von paramagnetischer NMR-
Spektroskopie in der Wirkstoffentwicklung. Für die Strukturanalyse von PEX14-Inhibitorkomplexen 
wurden verschiedene Methoden zur Konjugierung paramagnetischer Lanthanid-Bindungsmarken 
untersucht und der Nutzen struktureller Informationen aus Pseudocontact Shifts und Paramagnetic 
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Relaxation Enhancement bewertet. Lanthanid-Tags wurden auf PEX14 und eine Cysteinmutante davon 
aufgetragen und gemessen, um strukturelle Information für die Modellierung der Bindung der 
Fragmente zu erhalten. 
Wassermoleküle spielen eine wichtige Rolle bei den Bindungseigenschaften von Protein-Ligand-
Komplexen sowie bei der Dynamik und Faltung von Proteinen spielen, was wertvolle Informationen 
für die Wirkstoffentwicklung liefert. Während hochauflösende Kristallstrukturen Informationen über 
die Position von Wassermolekülen liefern, fehlt dies bei niedrigauflösenden Kristallstrukturen, NMR 
und Cryo-EM Strukturen. Ein deep learning Algorithmus, der die Position von Wassermolekülen auf 
NMR- und Kryo-EM-Strukturen voraussagt, wurde an hochaufgelösten Kristallstrukturen trainiert. Der 
Ansatz wurde mit experimentellen Strukturen von IMP-13 und der T. cruzi PEX14 N-terminalen 
Domäne validiert. 
Die in dieser Arbeit vorgestellten Ergebnisse liefern neuartige Erkenntnisse und Methoden zur 
Bewältigung aktueller Herausforderungen in der frühen Phase der Wirkstoffentwicklung und können 
auf viele andere Systeme übertragen und angewendet werden. 
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1. Introduction 
In the following section, a description of the process of early-stage drug discovery will be presented, 
along with a background of the biology of key proteins characterised in the thesis. 
  
Drug development 
Drugs have been used by humans as remedies to various ailments since ancient times, mainly using 
natural products from plants and animals. Many of these traditionally-used plants contain active 
ingredients that were later extracted and synthesised artificially or optimised for stronger effects. 
Willow, used for its painkilling and anti-inflammatory properties for more than three and a half 
millennia, contains salicylate, similar to aspirin. In the 5th Century BC, Hippocrates wrote about a 
powder that could be extracted from willow that was bitter and had these same properties. More 
than two millennia later, Reverend Edmond Stone wrote about its antipyretic qualities (Stone 1763) 
and in 1828, it was first isolated in its pure form in Munich. Salicylic acid was then purified in larger 
quantities in 1838. This was further developed from this acidic molecule that caused irritation in the 
stomach into the neutral formulation sodium salicylate by Felix Hoffmann of Bayer, who patented and 
marketed the drug as aspirin (Desborough and Keeling 2017). 
Later, drugs started to be produced synthetically, allowing for production on a large scale, without the 
need for large quantities of natural-product-producing organisms. This also led to the opportunity to 
embellish and improve molecules until medicinal chemists were able to design and build their desired 
molecules from scratch, based on structure; more than half of FDA-approved drugs now have a 
synthetic origin (Bade et al. 2010). Now, the ability to synthesise a required molecule is no longer the 
largest hurdle to overcome, with other points in the drug discovery process taking that role, as the 
methods for finding and developing possible drugs alter over time. 
Early-stage drug discovery pipeline 
 
Figure 1.1: Fragment-based drug design in early stage drug discovery. 
9 
 
A typical drug discovery pipeline consists of a method of screening for possibilities, followed by 
determining how it is acting. In some cases, this involves determining binding partners; in others, this 
requires structure determination, depending on the screening method that is used. Thereafter, a 
medicinal chemistry programme is normally carried out to further improve binding and 
pharmacokinetic and pharmacodynamics properties, before iterative testing, characterisation and 
improvement occurs (Fig. 1.1). Once the molecule is optimised to the point of being a lead molecule, 
the pharmacological absorption, distribution, metabolism, excretion and toxicological (ADME-TOX) 
parameters are characterised and further improved, where possible, before entering in vivo testing 
and clinical trials. Here I will focus on the early stages of drug discovery from screening to lead 
molecule identification. 
High-throughput screening 
High-throughput screening (HTS) can be either a target- or phenotypic-based approach that is 
normally automated. It is used to screen vast libraries of drug-like molecules and has increased in 
prevalence since the 1980s (Chatterjee and Ganguli 1986; Burch and Kyle 1991). These drug-like 
molecules are generally chosen to have drug-like properties, for example using Lipinski’s (Lipinski et 
al. 2001) rules and variations thereof, and to be chemically diverse.  
Some libraries include drugs that have been used for other purposes, or which have been developed 
and dropped at a later stage in the development process. This method has the advantage that the 
molecules are already drug-like and so suitable for in vitro, cellular or in vivo screening, but it also has 
the disadvantage that many of the molecules are similar as they have been designed for current 
targets, dominated by proteases and transcription regulators (Cudic and Fields 2009). This means that 
these libraries are less suitable for finding molecules for new drug target classes, for example protein-
protein interface (PPI) interactions, which unlike most enzymes have shallow binding pockets. The 
library can, however, be added to or designed with this in mind (Valenti et al. 2019), in order to 
increase the variety of molecules available in the library. The other disadvantage of this is that for 
relatively large molecules, it is unlikely that they will perfectly fit to the binding site, meaning that 
many promising molecule classes could be missed in this way. Given its relatively inexpensive nature 
for companies that already possess such a drug-like HTS library, this is nonetheless a beneficial 
method, and the fragment-based methods provide an alternative that partially solves this issue. 
Phenotypic screening 
Phenotypic screening involves testing an array of compounds on cells, tissue cultures or a living 
organism. These living assays are designed so that the cells or animals exhibit disease-like traits 
(disease phenotypes). Using a variety of techniques, the researchers can then determine whether the 
molecules added cause a phenotypic improvement. They can also simultaneously investigate possible 
side effects in the systems that they use. 
Early approaches of drug discovery were focused on phenotypic screening. Having fallen out of fashion 
as target-based drug discovery gained in popularity, phenotypic screening has now increased again in 
use, particularly in systems and diseases where a target protein is yet to be discovered (Zheng et al. 
2013). Once a molecule is found that has a phenotypic effect, target screening can then be carried out 
to determine the molecule in the cell or organism that is effecting that change, for example using 
drop-down experiments. Whilst experiments in mammals, for example mice, can be prohibitively 
expensive and ethically complex for large-scale screening, other organisms that share much of our 
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DNA, where relevant mutations with disease phenotypes can be added, can also be used. For example, 
C. elegans and Drosophila can now be used for large-scale screening (Carretero et al. 2017; Bangi 
2019), much like typical in vitro high-throughput screening methods discussed below. The other value 
of these models is that their translucency allows real-time tracking, so this can also be used, for 
example, for biogenesis or developmental phenotypic screening. Of course, drugs designed to combat 
infections are less suitable for screening in such organisms as the key processes in bacteria and 
parasites can vary substantially from mammalian and other eukaryotic processes. 
The disadvantage of phenotypic screening is that, as the target is not known, it can be challenging to 
develop and improve the molecule’s efficacy and its properties. If a structural improvement is desired, 
the target must be isolated, the structure of it and the complex with the ligand determined and then 
the structural improvement can occur. 
Some analyses have found that more first-in-class drugs were discovered using phenotypic screening 
than target-based screening (Swinney and Anthony 2011), while others have found the opposite (Eder 
et al. 2014), indicating that both play a significant role in the discovery of new drugs, although the 
output of FDA-approved drugs found through target-based screening is increasing. Target-based 
screening, including high-throughput screening and fragment-based screening, produces far more 
follow-up compounds than found using phenotypic screening. 
Fragment-based screening 
The libraries of successful or drug-like compounds and natural specimens used (Katz and Baltz 2016), 
combined with the huge chemical space available leads to many similar compounds being tested and, 
as the molecules are already drug-sized, this leaves little scope for further alteration without changing 
large sections of the molecule. It can also be very time and labour-intensive and methods have been 
developed to improve this. 
One such method is fragment-based drug screening (FBS) (Badger 2012; Peng et al. 2016; Erlanson et 
al. 2019). This involves testing smaller fragments, often containing only one or two functional groups 
(mass < 250 g.mol-1) against the target protein, in order to sample as much of the chemical space as 
possible in the first rounds of testing (Fig. 1.1). Various methods, X-ray crystallography and NMR 
prominent among them, are then used to determine which of these fragments bind to the target 
protein and, when possible, where they bind and whether they alter the binding site (Krimm 2015). 
This information can then be used to link fragments together that are in similar locations or grow 
fragments outwards into concave binding pockets or into active sites on the protein to increase 
binding affinity or improve pharmacokinetic properties. 
Fragment-based screening can be carried out using NMR, X-ray crystallography and other biophysical 
techniques, each with different advantages and disadvantages. Here, NMR techniques are used for 
screening, both ligand and protein-observed, to determine quickly and in solution whether ligands 
interact with the target protein. 
Fragment- and structure-based design 
With a variety of fragment and ligand hits from the screening methods mentioned, the next stage in 
the drug discovery process is to develop these hits into lead molecules (Krimm 2015; Erlanson et al. 
2019). With fragments, there are three main methods to this, often used in conjunction. These are 
merging, linking and growing of the fragments into larger molecules with better binding properties 
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(Fig. 1.1). In order to do this efficiently, the relative positions and orientations of binding should be 
known. This allows, for example, linking elements between two fragments to be designed to the 
correct length and to optimise possible interactions to the protein regions between the two binding 
sites. It also allows nearby binding pockets to be located, enabling the fragments to be grown or 
expanded into them, again maximising positive interactions. Merging requires overlap of binding 
positions of two or more fragments or ligands. For example, if two fragments overlap in such a way as 
to share one edge of an aromatic ring each, the two fragments could be merged to form a biaromatic 
ring system, along with any decorations on the ring systems. 
Structure-activity relationships (SAR) also play a key role in determining which route to follow in drug 
discovery (Hajduk 2006). For a given molecule, exit vectors are determined, which can be optimised. 
For example, with a phenol fragment, the exit vectors could simply be the para, ortho and meta 
positions. Each of these would be functionalised with a variety of functional groups and the binding 
affinity or other measure of activity measured. This leads to an SAR cascade. By systematically 
approaching this optimisation process, medicinal chemists can more rapidly get to a final molecule by 
ruling out classes and patterns, rather than testing every permutation in every position. 
 
Protein targets 
Two main protein targets, PEX14 and IMP-13 are addressed in this thesis, along with a protein 
characterised in a collaborative project, ph47phox. The background and disease relevance of these 
proteins are described below. 
Peroxisomal biogenesis in Trypanosoma 
Peroxisomes 
Peroxisomes are membrane-surrounded organelles found in both humans and the trypanosome 
parasites. They are located in the cytosol and are the location of many key processes and reactions in 
the cell. Key reactions such as oxidation of certain biomolecules and lipid biosynthesis occur here 
(Schrader and Fahimi 2008). Some of these reactions form toxic by-products, for example hydrogen 
peroxide, so further processing of these molecules must also occur within the peroxisome in order to 
prevent cell damage and death (Cooper 2020). It is therefore critical that all the required enzymes co-
localise in the peroxisomes, and that these reactions do not occur in the cytosol. 
Peroxisomes were first isolated by Christian René de Duve (De Duve and Baudhuin 1966), who 
developed the technique of cell fractionation. As the peroxisomes are denser than other cellular 
organelles, they could be separated from the rest of the cell contents in this way. They had previously 
been identified as organelles in 1954 by Rhodin using electron microscopy and were referred to as 
microbodies. Since their isolation and the analysis of the processes involved, several pathological 
conditions related to peroxisomes in humans have also been elucidated. The first of these was 
Zellweger Syndrome, first published by Goldfischer et al. (Goldfischer et al. 1973). This is linked to 
incorrect or absent lipid metabolism due to a reduced number of peroxisomes; Zellweger Syndrome 
leads to a huge number of defects, including renal and hepatic failure, musculoskeletal problems and 
death within six months. Other genetic conditions are also known, many of which cause significant 
defects and lead to a reduced life expectancy. Infantile Refsum’s disease, for example, leads to a life 
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expectancy of 10-30 years (Schrader and Fahimi 2008), whilst neonatal adrenoleukodystrophy is lethal 
in infancy (Aubourg et al. 1986). 
Trypanosoma 
The trypanosomes are single-celled parasitic protozoa that form the genus Trypanosoma. Their life 
cycle is complex and involves multiple organisms, normally with an insect as the vector or reservoir 
host (Radwanska et al. 2018). A variety of different vertebrates can be affected, including humans. As 
the disease progression, and form of the parasites, is multi-stage, the symptoms in humans are also 
seen as an acute and a chronic stage. In the initial period after infection, known as the acute stage, 
patients are either asymptomatic or suffer from cold- or flu-like symptoms including headache or 
general fatigue (Pinazo et al. 2017). Some patients experience lesions at the bite site or swelling 
around the eyes where the faeces of the insect vector enter and cause inflammation (Kennedy and 
Rodgers 2019). In these cases, the disease is more likely to be caught at the acute stage. After this, if 
left untreated, the disease enters the chronic stage. During this stage, the parasite is sequestered in 
the tissues, primarily in the cardiac and digestive muscle (Pérez-Molina and Molina 2018; Kennedy 
and Rodgers 2019). The chronic stage is again asymptomatic for some time, but this progresses to 
clinically observable forms. This can include cardiac abnormalities, oesophageal and colonic dilation 
and problems with the autonomic nervous system. In the end, this can lead to heart failure, 
haemorrhaging, arrhythmias and ultimately death. The main forms in humans are Human African 
Trypanosomiasis (HAT), caused by Trypanosoma brucei, and Chagas disease, caused by Trypanosoma 
cruzi. 
The vector host for Trypanosoma brucei is the tsetse fly, a blood-sucking insect found in much of 
tropical Africa. HAT is therefore found only in sub-Saharan Africa. In 1995, the WHO estimated that 
300,000 cases per year were occurring, whilst only 30,000 of these were diagnosed and treated (WHO 
2020a). Since then, the numbers of cases, thanks to increased control and information campaigns, 
dropped to 3796 reported cases in 2014, with under 15,000 total cases estimated. Whilst this is a 
positive trend, the disease was almost eradicated in the 1960s but, with a lack of interest due to the 
low number of cases, the numbers of cases gradually increased again. Therefore, despite the lower 
numbers and better treatment availability, complacency against the T. brucei parasite is not an option. 
A new oral treatment for T. brucei, fexinidazole, has recently been recommended for humans 
following clinical trials (European Medicines Agency 2018). It is hoped that this will replace previous 
drug regimens that were administered intravenously or by intramuscular injections. 
Trypanosoma cruzi is spread by the triatomine bug, as well as by congenital transmission from mother 
to child, and is found primarily in South America (Pérez-Molina and Molina 2018). However, it is 
believed that more than 300,000 people in the United States are infected with the disease, with cases 
also in Europe (Bern and Montgomery 2009). Antiparasitic treatment (Nifurtimox or Benznidazole) are 
very successful if given at the acute stage of the disease, as soon as possible after infection has 
occurred. These have treatment times of 60-90 days and common side effects, such as weight loss, 
insomnia, vomiting and neuropathy, which, given the minimal symptoms of the disease itself at this 
point, lead to problems with compliance (WHO 2020b). These treatments can be used during the 
chronic phase, but this is less effective and can only slow or prevent disease progression and not undo 
damage already caused. According to the WHO, an estimated 6-7 million people worldwide are 
infected with T. cruzi. New drugs with shorter treatment times, fewer side effects and drugs with high 
efficacy in the chronic stage of the illness are therefore desperately needed. 
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 Glycosomes and protein import 
As mentioned above, the reactions carried out in the peroxisome and the importance of co-
localisation of enzymes within these pathways make it crucial that protein import into the organelles 
is targeted and efficient. In the trypanosomal parasites, glycosomes resemble peroxisomes of human 
cells (Michels et al. 2005). The term peroxisomes is used both for the general classification and for 
peroxisomes in animals. From here onwards, I will therefore refer to the categories as peroxisomes 
(all), glycosomes (parasite) and mammalian peroxisomes (as in humans). These are ancestrally related 
membrane-bound organelles, where many of the key proteins and processes involved are conserved. 
The biogenesis and proliferation pathways, for example are highly conserved, with homologous 
proteins involved in protein import and membrane insertion seen, in some cases, across the kingdoms 
of life (Brown and Baker 2008; Walter and Erdmann 2019). The glyosomes have one key difference 
from mammalian peroxisomes: the glycosome is the location of a substantial part of the glycolysis 
pathway in protozoa. The degree to which they rely on this is dependent on the stage of the life cycle 
of the parasite, as the metabolic pathways alter as they go through the different phases (Haanstra et 
al. 2016). For example, the trypomastigote stage of T. brucei, which is the form that enters the 
bloodstream from the triatomine bug bite or other skin opening and travels in the bloodstream, is 
highly mobile and is 100% reliant on ATP production via this mechanism due to the high and conserved 
oxygen content in the mammalian bloodstream. It therefore has a high glycosome count, whilst the 
epimastigote stage (the uninfective stage in the digestive system of the insect vector) has a far lower 
concentration of glycolytic enzymes due to the absence of continuous glucose presence (the insect 
sugar levels peak after a meal and rapidly decline).  
Proteins involved in the biogenesis of peroxisomes are known as peroxins, or PEX, proteins. Currently 
37 peroxins are known in total to contribute to processes including targeting, insertion and import of 
required proteins, and division and proliferation of the peroxisomes (Kalel et al. 2017; Walter and 
Erdmann 2019). In order to be transported into the peroxisomes, the proteins must first be recognised 
and targeted. This occurs using peroxisomal targeting sequences (PTS). PTS1, the most abundant PTS, 
is recognised and bound by the tetratricopeptide repeat (TPR) domain of PEX5 in the cytosol (Fig. 1.2). 
The tail of PEX has been shown to have a WxxxF motif that binds to the N-terminal domain of PEX14 
(Neufeld et al. 2009; Neuhaus et al. 2014). PEX14 is tethered to the peroxisomal membrane, but its N-
terminus is soluble and assumed to be facing the cytosolic side of the membrane. On binding of these 
three partners, the targeted protein is imported through the membrane into the peroxisomal space. 
A second PTS, PTS2 is targeted in much the same way by PEX7, which in turn targets the PEX14 N-
terminal domain for import into the peroxisome (Walter and Erdmann 2019).  
In the case of the glycosomes, PEX14 and the membrane protein PEX13 form a “docking” complex in 
the membrane that aids with import. Molecular and structural details of pore formation and 
biogenesis (formation and proliferation) of the glycosome have not yet been elucidated. 
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PEX14/PEX5 interface and inhibition 
Glycosomes and the reactions that occur within are known to be essential to parasites. Dawidowski 
et al. showed, using a mixture of fragment and structure-based drug discovery, that small molecule 
inhibitors of the PEX14/PEX5 interface in T. brucei could be designed and synthesised, and that 
treatment of the bloodstream form of Trypanosoma brucei brucei with these small molecules led to 
glycosomal import defects and death of the parasite (Fig. 1.2) (Dawidowski et al. 2017, 2020). This 
highlights that disruption of the glycosomal import pathway is a valid target for further drug 
development campaigns in the trypanosomes. 
Due to the sequence similarity of human, T. cruzi and T. brucei PEX14, care must be taken to ensure 
that the molecules designed are as selective as possible for the trypanosomes over the human protein, 
in order to reduce the effect on peroxisomes in the human body. Peroxisomal protein inhibition in 
humans, given the severity of peroxisomal diseases described above, could cause potentially serious 
side effects. 
Metallo-β-lactamases 
The second protein target in the thesis is a metallo-β-lactamase (MBL). MBLs form a class of 
metalloenzymes that confers antibiotic resistance to bacteria. By cleaving the β-lactam ring on 
carbapenems, commonly considered the antibiotics of last resort, these critical drugs are rendered 
useless (Tooke et al. 2019). The protein has been found in every significantly populated continent 
(Zhao and Hu 2011) and is often co-expressed with other antibiotic resistance genes (Mendes et al. 
2004; Ho et al. 2014). Due to an active site with two zinc ions, these enzymes can be very difficult to 
model in silico, increasing the dependence on experimental techniques in drug discovery of this class. 
Figure 1.2: Schematic of PEX14 pathway. An import protein (orange) with a terminal PTS-1 peptide motif (red) binds to the PEX5 (blue) 
TPR domain. PEX5 then interacts with the PEX14 (green) N-terminal domain, leading to the tagged protein passing the membrane into 
the glycosome. When an inhibitor (pink) is added to block the PEX14-PEX5 interaction, the proteins do not pass the membrane and 
therefore build up in the cytoplasm, causing a lack of reactions in the glycosome and runaway reactions in the cytosol, leading to cell 
death. 
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Discovery of molecules to inhibit these enzymes would be highly beneficial as antibiotics that are 
rendered inactive by them could then be used again in combination therapy with the inhibitors (Tooke 
et al. 2019). This would have far-reaching benefits as both community and nosocomial outbreaks of 
antibiotic resistant infections in vulnerable populations could be far more easily brought under 
control, reducing the mortality of such events. 
Imipenemase-13 (IMP-13) is a member of this class of enzymes (Santella et al. 2011) and was 
previously not structurally characterised. This is a key target approached in this thesis. Due to the 
broad range of metallo-β-lactamases and their intrinsic similarities and differences, development of 
inhibitors requires an in-depth knowledge of the structure and function of different members of the 
class in order to determine which interactions are key when designing drugs and which play only a 
minor role. 
Crystallising IMP-13 with fragments was found to be challenging; the enzyme was instead studied in 
its apo state and in the presence of its natural substrates, the carbapenem antibiotics, in order to learn 
more about its mode of binding and dynamics in the different states. 
NADPH oxidase 2 complex 
In 1933, a process called a respiratory burst was first seen to occur in phagocytes (Baldridge and 
Gerard 1932), which leads to generation of hydrogen peroxide (Iyer et al. 1961); it was later seen that 
some isoforms produce superoxide (Babior et al. 1973) and some hydrogen peroxide. In 1987, it was 
noted that patients with chronic granulomatous disease, who have reduced bactericidal activity in the 
phagocytes, lack the respiratory burst function (Quie et al. 1967). Over time, the individual 
components of the complex causing this and the processes involved were elucidated. There are 
several NADPH oxidases with a variety of cofactors, but we focus on the NADPH Oxidase 2 complex. 
The function of this membrane-bound complex is to shuttle an electron from NADPH in the cytosol via 
Flavin adenine dinucleotide to oxygen on the outside of the membrane. This leads to production of 
reactive oxygen species (ROS). ROS have several uses in the body, from host defence to regulation of 
cell growth, but are also known to cause cell damage in many cases, leading to inflammation and some 
pathological conditions, such as diabetes and cancers (Block and Gorin 2012). Thus, this complex could 
be a potential drug target for such conditions when targeted to specific tissues. 
The NOX2 complex consists of membrane-bound NOX2 in a heterodimer with p22phox, also membrane-
bound (Fig. 1.3). These stabilise each other; neither NOX2- nor p22phox-deficient patients show 
significant concentration of either protein in the phagocytes as, when not in dimeric form, these 
proteins are targeted for degradation (Parkos et al. 1989). P47phox is found in the cytoplasm and binds 
to p67phox, the activator protein, and, in some cases, p40phox. In its unphosphorylated form, p47phox 
does not bind to the membrane-bound dimer. Upon phosphorylation, however, p47phox binds to 
p22phox, bringing p67phox in contact with NOX2 in the membrane, which is necessary for its activation. 
Rac GTPase also plays a role in activation of the NOX2 complex (Bedard and Krause 2007).  
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P47phox consists of two SH3 domains, as well as an autoinhibitory region (AIR) (Fig. 1.3A), with a phox 
region that binds to phospholipid membranes and a proline-rich region that binds to p67phox (Leto et 
al. 1994). The binding site for p22phox lies in a deep pocket between the two SH3 domains and is 
rendered inaccessible by the AIR. However, on phosphorylation of the AIR, the binding site then 
becomes accessible, allowing p22phox to bind, leading to activation of the NOX2 complex by p67phox. 
 
Fluorescence polarisation assays, along with cell-free activity assays have previously been used to 
screen for inhibitors of NOX2 by preventing binding of p47phox (Smith et al. 2012). This led to Ebselen 
(Sakurai et al. 2006) being highlighted as a potential drug for this purpose. Ebselen led to decreased 
activity of NOX2, as well as preventing localisation of p47phox to the membrane, indicating that it was 
preventing the binding of p47phox to the NOX2-p22phox dimer as intended. However no structural data 
was published to show the binding mode or mechanism. This nonetheless highlighted the validity of 
the use of p47phox as a drug target. 
  
Figure 1.3: Schematic of NADPH oxidase complex. A. p47phox domain structure. B. p47phox (orange) forms a complex with p67phox 
(blue) and p40phox (purple). The AIR domain of p47phox is phosphorylated and relocates allowing binding to p22phox (green). This 
brings p67phox into contact with NOX2 (red), which with Rac (light blue) forms the active complex, leading to production of ROS. 
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Major challenges in structure-based drug discovery 
With the improvement in knowledge of drug mechanisms, screening methodologies and medicinal 
chemistry, the major limiting factor in the early-stage drug discovery pipeline is structure 
determination of the complexes. The main methods for structure determination in drug discovery 
include X-ray crystallography and NMR, while cryo-EM is currently emerging and especially useful for 
large complexes. 
Out of these methods, X-ray crystallography is the oldest and most well-established. A protein is 
expressed and purified and incubated at high concentrations along with a crystallisation buffer. This 
is done using the sitting or hanging drop method, allowing a droplet of protein solution to steadily 
increase in concentration over time, allowing the droplet to reach super-saturation and crystallise 
(McPherson and Gavira 2014). These crystals grow in a repeating lattice structure, where each 
repeated block is referred to as a unit cell. The translational and sometimes rotational symmetry of 
these crystals is a huge benefit in solving the structure of the protein. However, the rigid formation of 
the crystal lattice can lead to artefacts caused by interactions between molecules within and between 
unit cells. It also hides any dynamics in the system. The crystalline environment is vastly different from 
a cellular environment, but the information gleaned from crystals can be incredibly valuable in 
understanding possible stable forms of the protein. The other key information that can be gained from 
crystal structures is the position of water molecules in the first hydration shell and other binding or 
interacting molecules. Water molecules that bind favourably in a specific position due to hydrogen 
bonding with the surface of the protein can be seen in medium- to high-resolution structures, giving 
further insight into how binding of a ligand affects this water envelope. This is an effect not seen in 
NMR or in cryo-EM. The challenge with crystallography for the purpose of studying fragment-protein 
complexes is that weak fragment binders often require very large concentrations of fragments, leading 
to crystallisation artefacts, as well as being difficult to crystallise, especially where crystal contacts 
would be disrupted by binding. 
NMR is a commonly-used alternative. NMR has the advantage that dynamics and conformational 
changes can be studied, both alone in solution and on interaction with ligands or fragments (Ludwig 
and Guenther 2009). This can be critical in some drug discovery projects, for example where a protein 
must be stabilised in its inactive conformation in order to prevent its biological activity. Both active 
and inactive conformations must be studied in this case, as well as the dynamics between the two 
states. Lower ligand and protein concentrations can be used than in crystallography, leading to fewer 
artefacts as a result of this. The environment is also more similar to a cellular environment, particularly 
where phosphate buffers at physiological pH are used. Intermolecular NOEs (Proudfoot et al. 2017), 
INPHARMA (Sánchez-Pedregal et al. 2005) and transfer-NOESY (Balaram et al. 1972; Ni 1994) are 
among key NMR techniques used to study ligand-protein interactions, either to detect binding in 
screening or to gain some information on the mode of interaction. This can provide important 
information about the mode of binding and the effect this could have on the activity of the protein. 
However, weak binders can be challenging to work with as a result of their transient interactions, 
which often leads to a very small bound population. Where only the bound state is measured, for 
example in the case of intermolecular NOEs, this leads to difficulties in obtaining a signal and long 
experimental times.  
Where direct structural methods are not suitable for the system, indirect experimental or 
computational approaches can be used to gain insight into binding of ligands. This includes 
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comparisons of fragments with available substrate or larger ligand complex structures and in silico 
modelling. Larger binding partners (either biomolecules or larger ligands) often bind much more 
tightly and with less flexibility to the target protein. This can lead to easier crystallisation of the 
complex due to more favourable interactions, fewer flexible regions or larger occupancy of the bound 
state. Larger occupancy of the bound state also aids NMR methods such as intermolecular NOE 
methods. The key interactions and dynamics properties of the system elucidated by either method 
can then be used to predict fragment or ligand behaviour and to develop further screening methods, 
as well as instruct medicinal chemists about key interactions within the binding pocket. In silico 
modelling also helps hugely with this, allowing structural biologists to predict the most likely binding 
poses of the ligand in comparison to the substrate and the protein structure. 
 
Aims of the thesis  
The thesis addresses a number of challenges in early-stage drug discovery, applied to important 
current drug targets. IMP-13, due to difficulty in crystallisation with the available fragments from the 
original drug screen, was lacking structural information to further the drug discovery project to 
develop inhibitors. In order to enable rational structure-based drug discovery for IMP-13, crystal 
structures of IMP-13 in complex with its natural substrates are solved and presented, along with other 
structural information, such as in silico modelling and NMR measurements to gain sufficient insight 
into the mode of interactions. This will allow the future expansion of the current fragments into hit 
and lead compounds while an understanding of the mechanism may also lead to the ability to 
streamline and find new fragments that bind in the active site and are most likely to inhibit the protein.  
The thesis also aimed to structurally characterise T. cruzi PEX14 and screen for potential fragment hits. 
NMR and crystallography are both used for characterisation and a variety of NMR methods for 
screening. Further characterisation of compound hits, in terms of binding parameters and structural 
features is carried out. Due to the weak binding and optimal single cysteine site, the use of both new 
and established paramagnetic tags for this protein is tested. In still on-going work the utility of 
paramagnetic restraints to define ligand binding poses is analysed. The theory and applications of 
paramagnetism in current drug discovery are reviewed. 
The importance of the water envelope of proteins on ligand binding has been exploited by a deep 
learning algorithm to determine water binding sites on protein structures in the absence of electron 
density. The algorithm is tested on published structures in the pdb and on presented crystal structures 
of IMP-13 and PEX14 to determine its applicability in a variety of molecule classes. 
The development and application of paramagnetic NMR and a deep learning algorithm to the project’s 
drug targets aims to demonstrate the utility of the methods, whilst highlighting and building on 
existing knowledge. This work will also provide new structural information and fragment hits for 
further use in drug discovery in building new ligand molecules to take further towards the clinic. 
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2. Methods 
This chapter summarises the background and broad experimental setup for the data collected for the 
papers presented in this thesis. Detailed experimental information can be found in the methods 
sections of the respective publications. 
 
Protein expression, purification and quantification 
Proteins were expressed using recombinant expression in E. coli cells. Plasmids were transformed into 
DH5α cells for plasmid amplification and the genetic material isolated. For expression, BL21 cells were 
used. 
For use in crystallography and for ligand-observed NMR methods, protein without isotope labelling 
was expressed using autoinduction medium (Studier 2005). For protein-observed NMR experiments, 
15N-labelled protein was produced with 15N autoinduction medium or, where required, 15N13C-labelled 
protein was produced using M9 minimal medium, supplemented with 15NH4Cl and 13C-glucose. 
After expression, cells were lysed with sonication and affinity chromatography with Ni or Zn NTA beads 
was used for initial purification. Size-exclusion chromatography was used for a further purification 
step. Purity and construct size was checked using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and the concentration was measured using a Thermofisher Nanodrop 
2000. 
All proteins were stored frozen in NMR buffer (HEPES for IMP-13 and phosphate NMR buffer for 
PEX14) at -80 °C. Fragments were stored at -20 °C at 100 mM in d6-DMSO, while ligands were stored 
at 50 mM in d6-DMSO, also at -20 °C. 
 
X-ray crystallography 
X-ray crystallography is a proven technique in macromolecular structure determination, from proteins 
to protein-peptide complexes and even nucleic acid structures. It relies on the discovery of many 
prized, sometimes Nobel-award-winning, scientists (Jaskolski et al. 2014), including the discovery of 
X-rays by von Laue, and further on the development of Bragg’s law to calculate the structure of a 
crystal lattice. From this, the field developed as Rosalind Franklin measured DNA crystals, allowing 
Watson and Crick to determine its double helix structure (Watson and Crick 1953). 
Currently a large array of software packages is available to solve the required equations, reducing the 
numerical and algebraic workload of the process for the end user significantly (Kabsch 2010; Adams 
et al. 2011). However the underlying principles remain the same. 
The diffraction pattern (Fig. 2.1) from an X-ray measurement is in inverse space, meaning that the 
closer together the reflections are, the larger the unit cell is. This means that salts have very largely 
spaced diffraction patterns, whilst protein crystals lead to a much finer array of spots (Dauter 2017). 
These reflection spots are very rich in information – their position describes the crystal lattice and the 
symmetry of the crystal, whilst the intensities hold information on what is within the crystal unit, i.e. 
the geometry within the unit cell. However some information is not held within: the phasing. This can 
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be carried out manually using heavy atoms or molecular replacement can be used. This means that 
phases from previously solved structures that are similar in structure can be used in further structure 
determinations. The spots must be indexed, then integrated to find their intensity for use in the 
further calculations. By repeated manual refining of the molecules into the electron density and 
refinement calculations, the structure slowly improves until completion (Fig. 2.1). 
 
 
Obtaining crystals 
The process of obtaining crystals normally involves, after obtaining pure, stable protein, screening 
under a variety of different conditions to find a condition in which regularly-shaped crystals form, 
where possible avoiding thin needles due to the difficulty in measuring them with a fixed-width X-ray 
beam. There are two common procedures for the crystallisation itself – the hanging drop and the 
sitting drop (McPherson and Gavira 2014). 
In the case of the sitting drop (Fig. 2.1A), a reservoir of the screening condition is set up with a small 
shelf slightly raised from it. On this shelf, a small drop of protein solution is mixed with a small volume 
of the screening condition, before being sealed and left in the required conditions (normally room 
temperature or cooled to around 4 °C) for the crystals to grow. As the sitting drop is a mixture of the 
screening condition and the protein solution, the concentration of the screening solution is higher in 
the surrounding reservoir that it is in the protein droplet. Therefore, in order to reach equilibrium, 
water from the droplet evaporates, increasing the concentration of both the ions and the protein in 
the drop. As the concentration reaches supersaturation, the protein can start to fall out of solution 
and crystallise. 
The principle of the hanging drop method (Fig. 2.1B) is much the same – vapour diffusion leads to 
supersaturation of the droplet and therefore crystallisation of the protein. However the setup of the 
drops themselves is different. Instead of sitting on a shelf or support above the reservoir, they are 
Figure 2.1: X-ray crystallography pipeline. Using either sitting (A) or hanging (B) drops, small drops of protein and reservoir solution are 
mixed and left to form crystals (C). These are frozen and taken to a synchrotron, where diffraction patterns are measured (D). The 
diffraction patterns represent electron density (E), into which protein molecules can be fitted and refined (F). These can then be 
represented in a variety of ways (G, H). 
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suspended from a cover slip above the reservoir. In practice, this means that a small volume of the 
protein, mixed with a small amount of the given reservoir solution, are placed on a thin cover sheet 
that is then upturned onto the plate, so that the drop is hanging from it. The surface tension and 
friction of the drop therefore prevent it from dropping. This does however mean that the drop size, if 
too large, can lead to loss of the sample. As these are normally prepared manually, whilst sitting drop 
plates can be prepared robotically, this is less suitable for large-scale screening campaigns. However, 
some proteins or complexes are seen to crystallise better in a hanging drop set-up. 
In order to reduce dynamics in the protein system further and to minimise damage caused by the 
heating effect of the X-ray beams, the crystals, once fished from their droplets, have a cryo-protectant 
added to them, if not already present in the crystallising condition, and are then frozen in liquid 
nitrogen. The crystals are cooled during measurement by a cryogen stream. 
Crystallisation with ligands 
It is often the case that in macromolecular structure determination, the required or desired structure 
consists of a complex with a peptide or small molecule ligand. There are multiple ways to obtain such 
structures, namely soaking or co-crystallisation (Rodrigues et al. 2018). 
Soaking is the addition of the peptide or small molecule to the pre-formed apo crystal structure. In an 
apo crystal, the unit cell of the protein is already in a stable state, with crystal contacts maintaining 
the interactions between protein molecules, both within and between unit cells (Müller 2017). The 
protein molecules, thanks to their lack of tessellation properties have channels between them within 
the crystal lattice, where solvents and other small molecules can pass. While some solvent molecules 
and ions maintain a relatively favoured position in different unit cells within this lattice when cryogen-
cooled due to particularly strong interactions, at room temperature the crystals still maintain some 
dynamic character, particularly in the solvent channels. This opens the possibility of introducing small 
molecules into the lattice once the crystals are formed. Ligand, fragment or peptide solutions are then 
added to the crystal and left to incubate for a period of time before freezing to allow the molecule to 
diffuse through the protein. This approach requires a reliable condition for production of apo crystals 
and the binding site must be accessible via the solvent channels in the crystal. It also is essential that 
the ligand does not cause a large conformational change in the protein that would disrupt the protein 
crystal, leading to either cracking of the crystal or a loss of diffraction. 
Co-crystallisation on the other hand involves the addition of the additional molecule before the 
crystals are grown. Typically, the ligand or peptide is added in large excess to the protein solution, the 
mixture is incubated for a time, and in some cases further concentrated, and then crystal plates are 
set up. This allows for the formation of a complex, which then together forms crystals maintaining this 
complex arrangement. This leads to the formation of crystals of the complex even when the binding 
site in the apo symmetry state is obstructed by other molecules in the unit cell, although can lead to 
a lower ligand occupancy (Müller 2017). The disadvantage of this method is that it works mainly with 
ligands and peptides that have a high affinity for the protein; the complex formation must be more 
stable than the formation of the crystal contacts in the apo state for the position of the ligand to be 
maintained during crystal formation. It is therefore not as useful as soaking in the case of fragment 
crystallisation, but in the case of known substrates or very strong binders can work very well. 
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Experimental outline and software 
Screening for crystallisation conditions was performed using commercially available buffer sets in a 
sitting-drop vapour diffusion setup. For co-crystallisation screens, compounds were added as either 
powder or DMSO solution. 
Diffraction data reported in this thesis were taken at the ESRF (Grenoble, France) at the ID30b 
beamline and at the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) on the X06SA 
beamline. The data was indexed using XDS (Kabsch 2010) and scaled using XScale or Aimless. The initial 
phases were obtained using molecular replacement carried out using molrep or Phaser, with TbPEX-
14 (PDB ID: 5L87) (Dawidowski et al. 2017) as the search model for TcPEX14 and PDB 1DD6 for the 
IMP-13. For additional IMP-13 structures, apo IMP-13 was used as the search model. Manual 
rebuilding using electron density maps was carried out in Coot (Emsley et al. 2010). Elbow was used 
for obtaining restraints for small molecules in the crystallisation conditions. Further refinements were 
carried out using Phenix Refine (Adams et al. 2011) or Refmac (Winn et al. 2003) with proSMART 
(Nicholls et al. 2012) used to generate additional restraints. Five percent of the reflections were used 
for cross-validation analysis. The final model of TcPEX14 was deposited in the PDB under code 6ZFW, 
which will be released on publication of the Zaucha et al. article. Final models of the apo and complex 
structures of IMP-13 were deposited under accession numbers 6R79 and 6R78 for apo and 6R73, 
6RZR, 6RZS and 6S0H for meropenem, imipenem, ertapenem and doripenem bound forms, 
respectively in the Protein Data Bank. 
 
NMR 
Basic principles 
Nuclear Magnetic Resonance (NMR) experiments have become a key source of information in 
structural biology in recent years. It relies on the principle of ‘spin’. Each sub-atomic particle has a spin 
value. When these are paired (i.e. both the number of neutrons and the number of protons are even), 
the nucleus has spin 0. If either or both of these numbers are odd, the nucleus has an non-zero spin 
value,  (Keeler and Wothers 2013). 
The value of  can be any half-integer (…-1, , 0 , , 1… etc), but in biomolecular NMR, we normally 
focus on spin  nuclei, for example 15N, 1H, 13C and 19F. I will therefore focus on this situation. For a 
nucleus with spin  within a magnetic field, the energy levels are split into  possible values, 
meaning that the spin  nuclei have two spin combinations (Fig. 2.2). In the absence of a magnetic 
field, these states have the same energy and so a statistical Boltzmann distribution leads to identical 
populations in each spin combination. In the presence of a magnetic field however, these 
combinations have distinct energy levels. The difference between these energy levels is equivalent to 
the Larmor frequency, , where  is the gyromagnetic ratio, an intrinsic property of nuclei, 
 is the reduced Planck’s constant and  is the external magnetic field strength. This means that the 
higher the magnetic field strength of the spectrometer, the larger the difference in energy. The spin 
states in which the spins partially align with the magnetic field are marginally lower in energy, leading 
to a slightly larger occupancy of this spin state. 
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By inducing a change of spin alignment using a radio pulse of frequency , spins 
are flipped from the lower energy level to the higher level. The decay of the spins from this high energy 
state back to the lower energy state leads to a measurable signal that can be transformed into a 
spectrum, where slight differences in chemical environments are measured as small differences in 
frequencies arriving at the detector. 
 
The Fourier transform (FT) of these data can be shown as a spectrum, depicting each environment of 
the chosen nucleus type as a single peak. The disadvantage of this now-simple method is that as target 
molecules increase in size, the number of peaks increases hugely, leading to significant overlap of 
peaks and difficulties in interpretation. 
Multi-dimensional protein NMR 
The development of more advanced pulse programs and improvement in isotope labelling (Otting and 
Wüthrich 1990; Ikura et al. 1990; Pardi 1992; Sattler et al. 1999; Lacabanne et al. 2018) have led to 
more subtle and specific measurements being possible and has increased the maximum protein size 
for such studies. Two-dimensional spectra in which magnetisation is transferred via bonds between 
pairs of nuclei, for example between 1H and 15N (Bodenhausen and Ruben 1980), enabled significant 
reductions in overlap of peaks in spectra of large molecules and led to the uprise of biological 
macromolecule studies. 
Further progress in computing power and spectrometer hardware and pulse programmes led to 
higher-dimensional spectra (Oschkinat et al. 1988), once more reducing overlap between signals and 
increasing the capability of studies of larger molecules. The coupling of magnetisation in this way 
(through-bond or through-space) can be used to study the structure of biological macromolecules, 
including RNA and proteins, in solution (Barbieri et al. 2004). The benefit of this in comparison to X-
Figure 2.2: NMR basic principles. A nucleus of spin half has one energy level in zero magnetic field. In the presence of a magnetic field, 
this splits into parallel and antiparallel states with different energies with an energy difference of . The larger the field, therefore, 
the larger the energy difference. 
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ray crystallography is that the conditions of the samples are much closer to the cellular environment 
than those used in crystallography. In order to assign each resonance in a 1H, 15N 2D correlation 
experiment, for example, 3D experiments such as HNCACB and CBCACONH spectra are used (Grzesiek 
and Bax 1992). These involve transfer of magnetisation along the chain of the molecule in the order 
referred to, so from amide H to amide N, further to the Cα and then to the Cβ in the case of HNCACB. 
CBCACONH spectra link the Cβ and Cα of the previous amino acid ( ) with the N and H of the 
current amino acid ( ). By overlapping the two spectra, this enables ‘walking’ along the chain of the 
molecule, which allows the individual residues to be assigned due to additional intrinsic properties of 
different amino acid types and knowledge of the amino acid sequence. 
For TcPEX14 backbone assignment 1H,15N 2D correlation experiments, 3D 15N-edited spectra, HNCA, 
HNCACB and CBCACONH experiments were recorded on uniformly 15N,13C-labelled samples on Bruker 
Avance III 800 MHz spectrometer (1H frequency 800 MHz) equipped with a 5 mm TCI cryoprobe. 
Samples at 600 μM were prepared in NMR phosphate buffer supplemented with 10% D2O. Spectra 
were processed using NMRpipe (Delaglio et al. 1995) and nmrDraw and assignments made using CCPN 
Analysis (Vranken et al. 2005). Amide assignments are deposited in the BMRB under deposition 
number 50345 and will be released upon publication. 
Backbone assignment experiments of IMP-13 are described in the article Structure and Molecular 
Recognition Mechanism of IMP-13 Metallo-β-lactamase (Softley et al. 2020b). 
Heteronuclear NOE 
Heteronuclear NOE (hetNOE) experiments are used to study the flexibility of different regions of a 
protein (Neuhaus and van Mierlo 1992; Farrow et al. 1994). The {1H}-15N heteronuclear NOE is 
commonly used to study the protein backbone flexibility by recording two 1H15N correlation spectra, 
normally in an interleaved fashion, with one including proton saturation {1H} and the other not. The 
comparison of the intensity of these two spectra gives the NOE value: a measure of the motion of the 
N-H bond vectors within the molecule. In areas where the protein is more flexible than other regions, 
the N-H bond will undergo more motion, leading to a decreased NOE value in comparison to less 
flexible regions: 

	
,  
where is the intensity of a peak in the spectrum measured with proton saturation and  is the 
intensity in the spectrum without. 
Paramagnetic NMR 
One NMR method investigated in detail in this thesis is the use of paramagnetism in drug discovery 
(Fig. 2.3). A protein is tagged and the paramagnetic effects, namely pseudocontact shifts, residual 
dipolar couplings and paramagnetic relaxation enhancements are measured on the protein and, in the 
case of drug discovery, on the fragment or ligand. As these effects provide distance- and/or angle-
dependent restraints, they are very informative and can be used for structure calculations or guided 
docking. This could be particularly useful in drug discovery due to the difficulties involved at the 
structure determination stage and the fact that, unlike chemical shift perturbation studies, the effects 
are not affected by allosteric changes. 
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Paramagnetism in NMR and its various applications in drug discovery are discussed in detail in the 
article Paramagnetic NMR in Drug Discovery (Softley et al. 2020a), with a summary on page 33. 
 
 
In order to utilise the effects of paramagnetism in protein NMR, a paramagnetic centre must be 
inserted using a paramagnetic tag, with the exception of the case where a natural metal binding site 
is present. A variety of tags are available, each with different properties, some of which are depicted 
in Fig. 2.3A. The tags shown here are single-point binding tags that bind to Cys residues. In the article 
Paramagnetic NMR in Drug Discovery, other tag types are also discussed. For the PEX14 protein target, 
however, single-point tags were deemed the most suitable due to the protein’s small size. Other tags, 
for example peptide tags or CLaNP-5, a two-site binding site, were not suitable as they would require 
mutation of multiple residues, potentially causing large disruption to the structure of such a small 
protein.  
 Paramagnetic tagging, NMR experiments and data analysis  
These experiments, described here in more detail, are part of still-ongoing work which is intended for 
publication in the near future. 
TcPEX14 constructs were tagged using DOTA-M8 (Häussinger et al. 2009) and vinyl-dipicolinic acid (Su 
et al. 2008), as well as the tag presented in the article by Denis et al. to introduce a paramagnetic 
centre into the protein. In all cases, samples containing BME were first incubated overnight at 4 °C 
Figure 2.3: Use of paramagnetism in fragment placement. A protein is tagged with a paramagnetic label (A), either with a metal (eg 
vinyl dipicolinic acid, DOTA-M8 or TAHA) or with a nitroxyl spin label (eg MTSL). Protein-observed spectra are measured, assigned and 
analysed (B, PCS shown). The metal position and tensor are then back-calculated (C). Ligand spectra can also be measured using ligand-
observed techniques (D). The proportion bound may need taking into consideration, and the position of the ligand on the surface of the 
protein can then be calculated or docked (E). 
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with TCEP, as BME has been found to maintain its interaction with the Cys residue even after 
attempted removal with buffer exchange columns or concentrate-dilute cycles. This interaction is also 
shown in the presented crystal structure of TcPEX14. After displacement with TCEP, this was buffer 
exchanged with a desalting column or concentrate-dilute cycles to buffers without reducing agents. 
In all cases, buffer exchange and removal of excess occurred with gravity columns PD-10 or NAP-5 (GE 
Healthcare) or with concentrate-dilute cycles. 
For paramagnetic tagging with DOTA-M8, a four-fold excess of tag was added and gently mixed and 
the mixture incubated for a reaction time of 4 hours at 25 °C. Excess tag was then removed before 
measurement. 
For paramagnetic tagging with vinyl dipicolinic acid, the protein was buffer exchanged into PEX14 
HEPES NMR buffer. A ten-fold excess of vinyl dipicolinic acid was added and incubated overnight at 25 
⁰C. The excess was removed, lanthanide metal ions (lutetium – diamagnetic, ytterbium and thulium – 
paramagnetic) in the form of chloride salts were added and any excess of ions then removed before 
measurement. 
1H,15N 2D correlation spectra were measured to check tagging was successful and temperature series 
were measured where necessary to aid with assignment of paramagnetic peaks from the diamagnetic 
reference. 2D TOCSY experiments using Dipsi2 cross-polarisation (Rucker and Shaka 1989) were 
carried out on the protein-ligand complex at 200 μM TcPEX14 and 360 μM fragment concentration to 
determine ligand peak assignments, as the peaks shifted significantly on protein binding. Tensors were 
calculated using FANTEN (Rinaldelli et al. 2015) and Paramagpy (William Orton et al. 2020) and 
visualised using Pymol (Schrödinger LLC). PCS-guided docking was carried out using Haddock (Schmitz 
and Bonvin 2011; Van Zundert et al. 2016). 
 
Drug discovery 
A variety of methods for drug discovery were covered briefly in the introduction; here I will focus on 
techniques used for early-stage drug discovery in the projects described. 
Fragment screening methods 
Fragment screening can be carried out using NMR, X-ray crystallography and other biophysical 
techniques. In our lab, we use mainly NMR techniques, both ligand and protein-observed. Ligand-
observed spectra have the advantage that no labelled protein is required, which aids the ease and 
cost of sample preparation for large-scale screening campaigns. Protein-observed is often more useful 
for smaller proteins, due to the relaxation-induced size limitations in NMR. Ligand-observed spectra 
include relaxation-editing (Hajduk et al. 1997), Saturation Transfer Difference (STD) (Mayer and Meyer 
1999), WaterLOGSY (Dalvit et al. 2001) and simple 1D 19F spectra (Ludwig and Guenther 2009).  
Relaxation-edited experiments are based on the principle that upon binding to a protein, the effective 
size of a ligand increases dramatically, leading to a slower tumbling rate and faster relaxation 
compared to when the ligand is measured alone. STD involves pulsing specific resonances within the 
protein (avoiding hitting the ligand signals; usually the methyl region is used), in order to saturate the 
protein. Due to efficient cross-relaxation spin diffusion within proteins, this leads to the entire protein 
being magnetised, along with any ligands that are bound, which are then visible in the spectra. Ligands 
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that are not bound to the protein are not magnetised, meaning that their signals are not visible in the 
spectrum. WaterLOGSY shows differential positive and negative NOEs to the ligand depending on the 
route of NOE transfer, in turn dependant on whether the ligand is bound or not. The water is 
magnetised and this can transfer to surrounding molecules either directly or indirectly. In the case of 
the ligand, this means that it can be transferred directly to the ligand, which due to the ligand’s small 
size results in a negative NOE or from the protein (to which the magnetisation has already been 
transferred from the water), which would lead to a positive NOE, due to the protein’s large size. 19F 
spectra can be used to look for shifts or changes in peak intensity; the advantage of 19F screening is 
that due to the absence of 19F signals from the protein, only the ligand is visible and the background 
is low, meaning that large mixtures of compounds can be tested at once and the spectra are easy to 
analyse. 19F is of particular relevance in drug discovery as many drug-like molecules contain fluorine 
or other halogen atoms. 
Protein-observed spectra, such as 2D correlation experiments (HSQC, HMQC) (Bodenhausen and 
Ruben 1980) tend to be used for screening smaller proteins and as an orthogonal method after testing 
with ligand-observed signals. It has the disadvantage that isotopically labelled protein is required, but 
the added advantage that, if the protein spectrum is already assigned, a chemical shift perturbation 
(CSP) analysis (Williamson 2013) can be carried out. This analysis highlights which amino acid signals 
have moved, giving an idea of the areas of the protein most affected. This can give an idea of the 
binding site, but CSP effects can also be induced allosterically so this is not always accurate. 
Fluorine Library Screening, Novartis 
The CF3 library screened consists of mixtures of compounds, designed to have clearly separated peaks 
and no cross-reactivity within each mixture. Initial screening was carried out on these compound 
mixtures, with validation being carried out using the single compounds. 
A 19F CPMG sequence was run twice on each sample with delays of 80 and 400ms and spectra were 
analysed using TopSpin NMR. Hits were then tested individually in the same manner. Hits observed in 
both mixture and individual screening were further screened by protein-observed NMR using 1H,15N 
2D correlation experiments. 
Helmholtz Zentrum München fragment library and compound testing 
The Helmholtz Zentrum fragment library was screened against 15N-labelled TcPEX14 using SOFAST 
1H,15N HMQC (Schanda and Brutscher 2005) spectra. Samples consisted of 190 µM protein with 
mixtures of 5 fragments. The DMSO signal was used as the lock signal and a reference spectrum of 
protein with 8µl DMSO was also measured. Hits were determined by manual inspection of the spectra 
using Topspin and deconvolution spectra of individual fragments in mixtures deemed to be hits were 
run at 1 mM fragment, supplemented with 10% D2O. 
Compounds from collaborators were tested with 1H, 15N 2D correlation spectra at 1:1, 3:1 or 1 mM 
compound, depending on the expected affinity and stage of development in the drug discovery 
process. The protein concentration was 100-200 µM for these spectra and a DMSO blank was 
measured for each set of tests. 
Biophysical and biochemical assays 
In order to characterise fragment or ligand hits from screening or optimisation rounds, further assays 
are required. These can be in vivo or in vitro and either direct or competitive binding assays. Two key 
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techniques used are AlphaScreenTM (Ullman et al. 1994; Bosse et al. 2002) and fluorescence 
polarisation (FP) (Lea and Simeonov 2011) assays. 
AlphaScreen™ 
AlphaScreen™ (PerkinElmer) is an assay technique that uses the short lifetime of the singlet state 
oxygen molecules to distinguish between binding and non-binding events (Bosse et al. 2002). Acceptor 
and donors bead are each bound to one of the two partners, the protein and its binder (Fig. 2.4), in 
our case PEX14 protein and the PEX5 WxxxF motif peptide.  
On laser excitation at 680 nm, the donor bead converts normal triplet oxygen into the excited singlet 
state. This is easily quenched on interactions with other molecules. However, if the acceptor bead is 
in close proximity to the donor bead as the excitation takes place, the singlet oxygen can react with a 
thioxene derivative present in the acceptor bead, leading to chemiluminescence at 370 nm. This then 
further stimulates other fluorophores in the acceptor bead leading to emission of light at 520 nm (Fig. 
2.4).  
 
 
Therefore, in the absence of an inhibitor, the beads emit light upon laser excitation, which can then 
be detected. When an inhibitor is added, the protein and peptide binding is obstructed, so a lower 
proportion of the beads are in close contact with each other. This leads to less light being emitted and 
so a lower intensity is recorded. As more inhibitor is added, more of the protein-peptide complexes 
dissociate, leading to a concentration-dependant change in the light emitted, which can be measured, 
plotted and fitted to a binding curve to determine the EC50 of this assay. 
Fluorescence Polarisation 
Originally described theoretically by Perrin in 1926 (Perrin 1926), fluorescence polarisation (FP) rests 
on the fact that polarisation of light emitted from a fluorophore is dependent on the rotation time, 
and therefore the size, of the molecule or any complexes that it forms (Lea and Simeonov 2011). 
Figure 2.4: AlphaScreenTM schematic. Donar beads are excited by a laser at 680nm. Normal triplet oxygen is converted into the excited 
singlet state. This is quickly quenched on interactions with other molecules, for example water. In the bound state, the donor and 
acceptor beads are close so the singlet oxygen can travel far enough to reach the accepter bead, triggering a reaction that leads to 
fluorescence at 520nm, which is measured. 
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Polarised light is beamed onto the experimental mixture. Light is then emitted from the fluorophore 
in a mixture of parallel and perpendicularly polarised light (Fig. 2.5). The parallel light intensity ( ) and 
the perpendicular light intensity ( ) can then be detected and used to calculate the FP value: 
 
This method has the advantage that it is independent of the concentration of fluorophores in the 
mixture. 
 
 
In drug screening, this is used to detect complex formation and inhibition. In our case, the peptide 
binder is bound to a fluorophore, the protein partner is also present and we make a concentration 
series of steadily increasing ligand concentration. In the absence of ligand, the peptide and its 
fluorophore bind to the protein, causing a specific FP readout. In the presence of binding ligand, the 
protein-peptide interface is disrupted, leading to a lower proportion of the fluorophore in the bound 
state. The average rotation time of the fluorophore is then significantly decreased due to the decrease 
in the effective weight of the complex, leading to an altered polarisation state which can be detected. 
This can be used to form a titration curve, allowing estimation of the IC50 from this data.  
 One significant disadvantage of this method is that many ligands fluoresce themselves and so would 
increase the amount of fluorescence and alter the proportions of parallel and perpendicular light. It is 
important to note this and to check after the measurements whether the overall fluorescence is 
increasing with increased ligand concentration and to account for this during the analysis.  
Figure 2.5: Fluorescence polarisation schematic. Polarised light excites a fluorophore that emits light that has different polarisation 
properties depending on the tumbling speed of the molecule(s) it is bound to. Polarisation filters are used to separate the emitted light 
into parallel and perpendicular contributions, which are detected and used to calculate the fluorescence polarisation value, FP. 
30 
 
Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is a method for monitoring molecular binding events and their 
kinetics. For direct binding studies, one binding partner is tethered to a film in a manner that minimally 
affects the structure and function. The other binding partner, or potential binding partner, is passed 
over the surface of the film, allowing interactions between the two to occur (Patching 2014; Nguyen 
et al. 2015). 
 
 
The principle behind the technique is dependent on oscillations of free electrons (or surface plasmons) 
at the interface of two materials. In this case, a light is shone through a prism and is reflected off the 
metal film, to which the molecules are tethered. At a fixed angle of incidence, the light excites the 
surface plasmons, leading to resonance, and an absorption band in the reflected light. By studying the 
intensity of different regions of the reflected beam, as well as the position of the absorption band over 
time, kinetics of binding events can be studied (Fig. 2.6). This can be measured with variation of 
concentrations in the flow-through solution to allow both on- and off-rates of binding to be calculated. 
Competition assays can also be carried out (Huber et al. 2015) using this method by altering the 
protocol, for example adding multiple molecules to the flow-through solution. 
  
Figure 2.6: Surface Plasmon Resonance schematic. One of the two binding partners is immobilised on a metal chip. Light is shone 
through a prism at the underside of the chip and the reflected light detected. An absorption band is present at a certain angle of 
incidence. The other binding partner is passed over the surface of the chip. As the binding alters, the position of the absorption band 
alters and is measured. When the soluble molecules are removed from the flow-through again, the proportion bound decreases again 
(for reversible binding), causing the absorption band to shift back towards its original position. This allows the measurement of kinetics 
as well as binding. 
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Thermal Shift Assay 
Thermal shift assays (TSA) are a way of measuring the thermal stability of a protein or complex and 
characterising protein ligand interactions (Huynh and Partch 2015). A dye molecule, for example 
SYPRO orange, is added to a protein solution. The hydrophobic properties of the dye leads to it binding 
to hydrophobic regions on the protein, causing measureable fluorescence of the dye. The protein-dye 
mixture is subjected to a temperature gradient over time; as the temperature increases, more of the 
protein denatures, leading to more exposed hydrophobic areas that would normally be buried within 
the protein. This leads to more dye binding and higher fluorescence. Above a certain temperature, the 
protein starts to aggregate, reducing the hydrophobic surface again, leading to a drop in fluorescence 
at very high temperatures. The melting temperature is taken as the turning point, or half-way point, 
of the initial increase in fluorescence as the protein denatures. By repeating the experiments with 
different conditions in the protein solutions, including different buffers or binding partners, the effect 
of those environments on the stability of the protein can be measured.  
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3. Publications 
This is a publication-based thesis. The work has been published in international peer-reviewed journal 
articles, which are summarised in this section. 
 
3.1 Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase 
The article, Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase (Softley 
et al. 2020b) was published in Antibiotic Agents and Chemotherapy and is found at 
http://aac.asm.org/lookup/doi/10.1128/AAC.00123-20 . The author of this thesis, Charlotte Softley, 
along with Mark Bostock and Krzysztof Zak, contributed equally to the original work and writing of this 
article. Charlotte Softley carried out molecular biology and protein expression and purification, 
crystallisation, data acquisition and analysis and preparation of the manuscript. In the following 
summary, citations of this paper are not included. 
 
Antibiotic resistance is a growing threat worldwide, leading to many treatable infections becoming 
more lethal as the resistance spreads into larger populations (Tooke et al. 2019). While many different 
antibiotic resistance mechanisms occur in bacteria, the WHO has formulated a list of critical pathogens 
for development of new antibiotics. On this list, all three categories of the most critical pathogens 
include carbapenem resistance (Tacconelli et al. 2017). Carbapenems are considered to be the drugs 
of last resort in the treatment of antibiotic resistant infections, but metallo-β-lactamases are 
rendering even these last-resort drugs useless (Mendes et al. 2004). MBLs are a family of 
metalloenzymes, including IMP-13 (Santella et al. 2011), that cleave the β-lactam ring of the 
carbapenems, preventing binding of the antibiotic to its intended target, the penicillin-binding 
proteins (Hong et al. 2015; Bush 2018). 
The article “Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase” 
presents a detailed structure and dynamics study of IMP-13 in the presence and absence of its 
substrates, the carbapenems. The interactions between IMP-13 and four carbapenems were studied 
by X-ray crystallography. Two apo structures were also presented, one with a critical flexible L1 loop 
in the open form, where the apical tryptophan residue was situated far from the active site, pointing 
into solution, and one with the flexible L1 loop in the closed form, positioned over the active site, with 
the tryptophan forming a tunnel between the binding site and free solution. This highlighted the 
presence of flexibility and dynamics of this loop, which were subsequently tested by NMR and 
molecular dynamics (MD) simulations. Both MD and NMR confirmed this hypothesis of the flexible 
loop, with the apo state having considerably more dynamic activity of the loop than in the presence 
of the antibiotic substrates. 
Furthermore the modes of binding to the antibiotics were studied. The carbapenem antibiotics have 
a carbapenem core motif consisting of decorated β-lactam and pyrroline ring moieties, as well as a tail 
region that varies more widely between different antibiotics in the class. Structural analysis indicates 
that the binding mode is highly conserved within the core motif, whilst the binding modes of the tails 
varied significantly as a result of the differing functional groups and orientations. Critical interactions 
include hydrophobic interactions of the rings and sulphur with the tryptophan and valines of L1, the 
interactions of the core’s carboxylic acid moieties to the zinc ions and to Lys 161 and the interactions 
of the N in the core to the Zn ions. The co-localisation of these key interactions in the core lends itself 
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to unspecific binding to different carbapenems, allowing the same enzyme to destroy an entire class 
of antibiotics, despite differing tail moieties. 
Comparison of this with existing structures of penicillin binding protein 3 (PBP) (Han et al. 2010) 
indicate that the tail regions are more critical to the binding to PBP, leading to different degrees of 
selectivity to different carbapenems. This could be key for drug discovery as the most important 
interactions differ in many ways between the carbapenems’ target molecules and the enzymes that 
degrade them. If differences can be exploited and similarities avoided, this could lead to development 
of further classes of molecules that are active against PBP without being destroyed by the MBL 
enzymes. 
 
3.2 Paramagnetic NMR in Drug Discovery 
The article, Paramagnetic NMR in Drug Discovery (Softley et al. 2020a) was published in the Journal of 
Biomolecular NMR and is found at https://doi.org/10.1007/s10858-020-00322-0. The author of this 
thesis, Charlotte Softley, and Mark Bostock contributed equally to this article. In the following 
summary, citations of this paper are not included. 
 
The process of structure-based drug discovery is a multi-step iterative process involving screening, 
structure determination of the complex, characterisation of the interaction with biophysical methods, 
medicinal chemistry to grow or link these fragments and ligands and then a repeat of the whole 
process (Krimm 2015; Erlanson et al. 2019). Many methods are available for all steps of this pathway, 
but in many cases, it is the structure determination of the complex that is the rate-limiting step. This 
is because weak-affinity ligands and fragments can often not be crystallised and NMR methods such 
as intermolecular NOEs (Proudfoot et al. 2017), whilst available, are often challenging and time 
consuming. 
Paramagnetism is a property of molecules where an unpaired electron is present. It causes magnetic 
properties in the presence of a magnetic field. As NMR uses strong static magnetic fields, 
paramagnetic samples show distinct characteristic alterations in the spectra. This includes shifts in the 
peaks of a protein 1H, 15N 2D correlation experiments (pseudo-contact shifts, PCS), an increase in 
relaxation and therefore a decrease in intensity of the signals (paramagnetic relaxation enhancement, 
PRE) and an alteration in the dipolar coupling of the signals (residual dipolar coupling, RDC) (Bertini et 
al. 2002a; Clore and Iwahara 2009). All three of these effects are distance and/or angle dependent. 
This means that by adding a paramagnetic centre, the extent of the PCS, PRE and RDC effects on each 
amino acid or ligand atom gives structural information on the molecule or complex. Whilst not yet 
widely used for this purpose, this can be exploited in drug discovery. 
The article ‘Paramagnetic NMR in Drug Discovery’ reviews the current methodology and applications 
in this area, from different methods available to introduce a paramagnetic spin label or metal ion, a 
brief description of the theory behind each paramagnetic effect and considerations that must be taken 
into account to literature examples of how these have been used and exploited in the drug discovery 
world. This includes works involving 1H, 15N, 13C and 19F and for PCS covers the entire range of 
interactions from slow exchange of strong binders through intermediate exchange to fast exchange 
of weaker binders. All three of these scenarios are found in drug discovery at different stages, making 
it critical for such methods to be applicable to all cases in order to speed up the drug discovery pipeline 
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using these methods. This comprehensive study provides clarity and examples for other scientists in 
the field to apply, as well as perspectives for the future. 
Figures are made, where relevant, using experimental data from TcPEX14, a peroxisomal protein in 
the T. cruzi parasite that causes Chagas Disease and is a key drug target in the fight against it. These 
data were collected as part of a drug discovery project on this target. Other figures are schematic 
depictions of the process. 
 
3.3 Deep Learning Model Predicts Water Interaction Sites on the Surface of Proteins 
using Limited-Resolution Data 
The article, Deep learning model predicts water interaction sites on the surface of proteins using 
limited-resolution data, was submitted to ChemComm on 24 June 2020. The author of this thesis, 
Charlotte Softley, and Jan Zaucha contributed equally to the original work and writing of this article. In 
the following summary, citations of this paper are not included. The structural analysis of the outputs 
of the algorithms, the crystal structure refinement TcPEX14 and structural biology and drug discovery 
discussion were carried out by Charlotte Softley, whilst design and development of the algorithm from 
the training set was carried out by Jan Zaucha. 
Interactions of water with proteins are known to have an effect on folding (Rhee et al. 2004), as well 
as binding of other proteins, ligands and nucleic acids (Hong and Kim 2016; Brini et al. 2017). 
Understanding where these water molecules are and how they interact, however, is less well studied. 
A prediction algorithm that could predict where waters on the surface of the protein lie could be highly 
beneficial in understanding the processes involved in binding, thereby significantly aiding in drug 
discovery efforts, where an understanding of factors affecting binding pockets and water networks is 
highly beneficial. 
The article ‘Deep learning model predicts water interaction sites on the surface of proteins using 
limited-resolution data’ by Jan Zaucha, Charlotte Softley et al. presents a water prediction algorithm 
based on a deep learning artificial intelligence model. A training set from the PDB is taken to allow the 
algorithm to learn from positions where water molecules are found in a wide subset of structures. 
From this, 2.8 million water molecules, each interacting with at least two protein atoms, were taken 
as the positive dataset and negative samples were chosen with a random sampling of a mesh around 
the protein, where the point chosen had no water molecule within 1.4 Å. An equal number of negative 
and positive training points were chosen.  
These positions were then analysed using information on their nearest neighbours. Up to 50 of the 
closest atoms, up to a maximum of 7.5 Å were included. Vectors from the position to each of these 
nearest neighbours, along with information on the character, for example hydrogens, aliphatic 
carbons, and the B factors of the atoms. These were passed through six different neural network 
architectures and analysed to choose the architecture that gives the highest classification accuracy. 
This architecture was then used. 
For evaluation, three PDB pairs of homologous proteins with different resolutions and methods were 
used. All structurally homologous proteins had been excluded from the training set to ensure that any 
information provided by the algorithm was from prediction and not just repetition of a protein in the 
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training set. The algorithm was run on the lower-resolution x-ray structures, and on cryo-EM and NMR 
structures, where waters are either limited or completely absent, and the results compared to the 
higher-resolution structures. 
A new crystal structure of the N-terminal domain of TcPEX14 (PDB: 6ZFW) is also presented. After 
testing of the algorithm on the three PDB pairs as described above, the TcPEX14 structure, with all of 
its water molecules removed, was provided to the algorithm for water prediction. The resulting 
predicted waters were then clustered and the results compared to TcPEX14, showing a recall of 0.27. 
This was then compared with the X-ray crystallography modules Coot Find Waters (Emsley et al. 2010) 
and Phenix Update Waters (Adams et al. 2011), both of which use the electron density map to locate 
water molecules, at a variety of resolution cut-offs. It was found that with a resolution >2.6 Å, a 
maximum of six water molecules were predicted with Coot and no water molecules at all with Phenix. 
At a resolution of <2.5 Å, the Phenix algorithm has a higher recall than hotWater, but Coot was not 
able to reach the same level of recall even at a resolution of 2 Å. 
The algorithm was run on a further structure, added to the PDB since the algorithm was developed. 
This was a crystal structure of IMP-13 (PDB: 6RZR) (Softley et al. 2020b), which has a binding pocket 
with a loop forming a tunnel-like structure over it. The original structure had an antibiotic, imipenem, 
bound. We found that the waters predicted using hotWater on the backbone structure of the pdb 
predicted water locations in the same place as the oxygen atoms of the antibiotic. On studying the 
other structures, we found that this was also the case with glycerol molecules in the PEX14 structure. 
 
3.4 Introducing the CSP Analyzer: a Novel Machine Learning-based Application for 
Automated Analysis of two-dimensional NMR spectra in NMR Fragment-based 
Screening 
The article, Introducing the CSP Analyzer: a Novel Machine Learning-based Application for Automated 
Analysis of two-dimensional NMR spectra in NMR Fragment-based Screening (Fino et al. 2020), was 
published in the Computational and Structural Biotechnology Journal and is found at 
https://doi.org/10.1016/j.csbj.2020.02.015. The author of this thesis, Charlotte Softley, contributed to 
this work in the form of contribution to the design, testing of the functionality and user interface, 
protein expression and purification, NMR screening experiments and manual analysis to produce 
training sets. In the following summary, citations of this paper are not included. 
A time-demanding initial task for NMR spectroscopists on drug screening projects is the screening and 
subsequent data analysis of the protein target. There are many ways to do this, including both protein- 
and ligand-observed methods (Ludwig and Guenther 2009; Gossert and Jahnke 2016). Typically the 
output for such a screen is hundreds to thousands of NMR spectra of samples containing the protein 
target with each of the members of the fragment or ligand library to be screened. For 2D protein-
observed spectra, the analysis for these datasets involves manual inspection of the spectra to 
determine whether signals have shifted on addition of the ligand. Whilst software is available for 
automatic or computer-aided processing of 1D datasets (Peng et al. 2016; East et al. 2019), this was 
lacking for 2D spectra. 
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As part of the study “Introducing the CSP Analyzer: a Novel Machine Learning-based Application for 
Automated Analysis of two-dimensional NMR spectra in NMR Fragment-based Screening” by R. Fino 
et al, an application, with front end written by Roberto Fino and back end written by Ryan Byrne, was 
produced to combat this need in NMR spectroscopy. Using training sets from drug discovery projects 
within the Helmholtz Zentrum München, a machine learning algorithm was designed and trained to 
automatically determine which spectra (and therefore which fragments or ligands) were deemed 
active and which were not, combined with the ability to manually check these assignments and label 
the spectra as active or inactive where these results were in conflict. This was then tested on new 
proteins to determine relevant statistical parameters. 
The software allows the user to upload hundreds of spectra of the same protein for analysis at once. 
Using the topspin peak picking, it shows schematically the test spectra in one panel, displayed one by 
one, each overlaid with the reference spectrum. It then automatically categorises them as hits or not 
hits and shows this as a diagram and numerically. The user has the option to scroll through each of 
the spectra and add manual labels where relevant. The software can be used to display just those 
labelled as hits or just those labelled as inactive for manual inspection. The number of peaks in each 
spectrum is also indicated so that errors in spectral data or processing can easily be identified. These 
data can then be printed to a spreadsheet for further analysis. 
The back end was designed using a machine learning algorithm. Initially a set of descriptors is defined, 
including the structural similarity index, which is a measure of similarity, including differences in noise 
and new or disappearing peaks. A paired-distance approach is then taken to further describe the 
similarities of the spectrum. The Hu moment estimation (Hu 1962) is used to compare invariant 
properties of the two spectra and as an additional metric, the Jensen-Shannon entropy difference 
between reference and test spectra is taken. This variety of metrics then undergoes dimensionality 
reduction and passed to a support vector classifier. In the training set, each spectrum is pre-labelled 
as active or inactive to allow categorisation of the test set. 
 
3.5 The Photocatalysed Thiol-ene reaction: A New Tag to Yield Fast, Selective and 
Irreversible Paramagnetic Tagging of Proteins 
The article, The Photocatalysed Thiol-ene reaction: A New Tag to Yield Fast, Selective and Irreversible 
Paramagnetic Tagging of Proteins (Denis et al. 2020), was published in ChemPhysChem and is found at 
https://doi.org/10.1002/cphc.202000071. The author of this thesis, Charlotte Softley, contributed to 
this work in the form of testing this tag, along with those designed and synthesised previously, on T. 
cruzi PEX14, along with calculating tensors where relevant using FANTEN. Some of these tags were 
found to have multiple conformations and, as such, were not reported in the final publication, due to 
the added complication of tensor calculation and flexibility not being conducive for the intended 
purpose. Precursors such as the dipicolinic acid-based tag, vinyl dipicolinic acid, were also tested on 
PEX14 to prove that the cysteine residue present was accessible enough to be successfully tagged. 
Paramagnetic tagging of proteins is a method being increasingly used in drug discovery and structural 
biology (Bertini et al. 2002b; Pintacuda et al. 2007). The addition of a paramagnetic centre causes 
changes to NMR spectra including PCS, RDC and PRE. Key properties of paramagnetic tags for use for 
these purposes include rigidity of the tag, sometimes with the ability to chelate or interact with an 
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extra residue on the protein for added rigidity, strong chelation of the metal ion, a stable bond 
between protein and tag (usually via a cysteine or lysine residue) and the chosen metal in the tag (Joss 
and Häussinger 2019). With regards to the metal, lanthanides or paramagnetic transition metals are 
usually chosen. 
In the article “The Photocatalysed Thiol-ene reaction: A New Tag to Yield Fast, Selective and 
Irreversible Paramagnetic Tagging of Proteins” by Maxime Denis et al., a newly designed and 
synthesised tag is presented. This tag is bound using a photo-catalysed thiolene reaction to cysteine 
residues on the surface of the protein. The thiolene reaction renders a stable thioether bond between 
the sulphur of the cysteine thiol and the double-bonded carbon of the tag. This reaction is irreversible, 
meaning that should reducing agents be necessary to stabilise other parts of the protein, they can be 
re-added after tagging without disrupting the ligation of the tag. 
The reaction itself takes place under UV radiation, speeding up the tagging process significantly. This 
is helpful for proteins that are unstable at room temperature overnight, as is necessary for some 
existing paramagnetic tagging protocols. Instead the reaction can run to completion within a few 
hours, with the added benefit that the measurement can be initiated on the same day as the tagging 
occurs. 
 
3.6 Developing Inhibitors of the p47phox−p22phox Protein−Protein Interac?on by 
Fragment-Based Drug Discovery 
The article Developing Inhibitors of the p47phox−p22phox Protein−Protein Interacbon by Fragment-
Based Drug Discovery (Solbak et al. 2020), was published in the Journal of Medicinal Chemistry and is 
found at https://dx.doi.org/10.1021/acs.jmedchem.9b01492. The author of this thesis, Charlotte 
Softley, contributed to this work in the form of validation screens of the hits from FP and TSA using 
NMR and contributions to the analysis of the tryptophan region. 
The production of reactive oxygen species by NADPH oxidase 2 causes a wide variety of disease states 
and damage within the cells, including inflammation, cancer, brain damage after traumatic injury and 
diabetes (Bedard and Krause 2007; Block and Gorin 2012). This complex consists of a membrane-
bound heterodimer of NOX2 and p22phox, along with three cytosolic proteins – p40phox, p47phox and 
p67phox – and Rac GTPase, a G protein (Groemping and Rittinger 2005; Bedard and Krause 2007). The 
interaction between p47phox and p22phox has been shown to be a key interaction in the formation of 
the active complex and a compound that inhibits this interaction, Ebselen, has been published (Sakurai 
et al. 2006; Smith et al. 2012), although not characterised in-depth. 
The p47phox protein is known to have two conformations: it has two domains, SH3A and SH3B which 
form one compact elongated form where the two domains are in close contact along their length and 
one ‘open’ form where the domains are separated (Groemping et al. 2003). On binding the p22phox 
peptide, p47phox adopts the more compact form. 
The study “Developing Inhibitors of the p47phox−p22phox Protein−Protein Interacbon by Fragment-
Based Drug Discovery” by Sara Solbak et al. shows a fragment-based drug design pathway, from 
screening using fluorescence polarisation and thermal shift assays to further characterisation and 
binding studies using NMR and surface plasmon residence studies.  
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The validation screens of the hits from FP and TSA using NMR showed that all of the tryptophans (and 
therefore the tryptophans of both SH3 domain regions) were being affected by the addition of two of 
the fragments, while only a subset of the tryptophans were affected by the other fragments, indicating 
that only one domain was being affected at a time.  
SAR was carried out on these two fragments and, after optimisations, a PEG-based linger was used 
between two molecules to form a dimer of each of the resulting fragments. This led to a large increase 
in affinity, with the best of these shown to have a Ki of 20 μM, comparable to that of the p22
phox 
peptide. 
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4. Conclusions 
Structural biology in the drug discovery process still faces numerous challenges. This thesis presents 
methodological solutions to several of these issues, along with applications to drug targets with 
relevance in infectious diseases. 
The antibiotic resistance protein IMP-13 was structurally characterised using X-ray crystallography in 
complex with several antibiotic substrates and in the apo state. The protein dynamics were also 
elucidated with the help of NMR. This allowed subsequent development of a novel screening 
approach, which has since widened the variety of fragment hits, including several that were able to 
be crystallised. 
The crystal structure of TcPEX14 was elucidated and its solution NMR assignment obtained. It was 
screened using ligand-observed CPMG and fluorine experiments in collaboration with Novartis, as well 
as with protein-observed NMR. As these structural information on these fragments could be obtained 
by neither X-ray crystallography nor intermolecular NOE experiments, the use of paramagnetic NMR 
was explored. PEX14 was tagged with several lanthanide-binding tags, including a novel tag. Existing 
theory and applications of paramagnetic relaxation enhancement and pseudocontact shifts in drug 
discovery were extensively reviewed. 
An algorithm for predicting water interaction sites on the surface of a protein using deep learning was 
developed and tested on crystal structures presented in this thesis, as well as on structures from the 
pdb. It was found that this was able to replicate key parameters found in the training set, such as likely 
distance from protein surface and number of proximal protein atoms, as well as providing better recall 
than standard algorithms using electron density at low resolutions. 
A software method for automatic analysis of 2D NMR screening data was also developed, trained and 
tested. Furthermore, a collaborative project on p47phox highlighted an additional use of NMR CSP data 
and led to the development of a compound series that bound simultaneously to two domains of the 
target protein, indicating the strength of multi-faceted approaches to challenging targets. 
In summary, whilst there are a huge number of problems and challenges throughout the drug 
discovery process, some caused by the characteristics of the biomolecular target and others by the 
intrinsic flaws in the techniques applied, by utilising new methodology or orthogonal methods in new 
ways, these can slowly be broken down and combatted in order to improve the drug development 
toolbox available. Whether combining in silico and experimental techniques, or chemical alterations 
of the target with standard structural techniques, novel integrative approaches can open doors to new 
knowledge and expertise, leading to faster development of new molecules to enhance or inhibit 
biomolecular activity.  
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5. Abbreviations 
AIR Autoinhibitory region 
Cryo-EM  Cryo-electron microscopy 
CSP  Chemical shift perturbation 
DMSO  Dimethylsulphoxide 
EC50  Half-maximal effective 
concentration 
ESRF  European synchrotron radiation 
facility 
FBS  Fragment-based screening 
FDA  US Food and Drug 
Administration 
FP  Fluorescence polarisation 
GTP Guanosine triphosphate 
HAT  Human African Trypanosomiasis 
hetNOE  Heteronuclear nuclear 
overhauser effect 
HMQC  Heteronuclear multi-quantum 
correlation 
HSQC  Heteronuclear single quantum 
correlation 
HTS  High-throughput screening 
IMP  Imipenemase 
INPHARMA  Interligand NOEs for 
pharmacophore mapping 
MBL  Metallo-β-lactamase 
MD  Molecular Dynamics 
NMR  Nuclear magnetic resonance 
NOE  Nuclear Overhauser effect 
NOESY  Nuclear Overhauser effect 
spectroscopy 
NOX2 NADPH oxidase 2 
NTA  Nitrilotriacetic acid 
PBP  Penicillin Binding Protein 
PCS  Pseudocontact shifts 
PDB Protein data bank 
PEG  Poly-ethylene glycol 
PEX  Peroxin protein 
Phox Phagocytic oxidase 
PPI  Protein-protein interface 
PRE  Paramagnetic relaxation 
enhancement 
PTS  Peroxisomal targeting sequence 
RDC  Residual dipolar couplings 
RNA  Ribonucleic acid 
ROS Reactive oxygen species 
SAR  Structure-activity relationship 
SAXS  Small angle X-ray scattering 
SDS-PAGE  Sodium dodecyl sulphate 
polyacrylamide gel 
electrophoresis 
SPR  Surface plasmon resonance 
STD  Saturation transfer difference 
T. brucei  Trypanosoma brucei 
T. cruzi  Trypanosoma cruzi 
TPR  Tetratricopeptide repeat 
TSA  Thermal shift assay 
WaterLOGSY  Water-ligand observed via 
gradient spectroscopy 
WHO  World Health Organisation
  
41 
 
6. Bibliography 
Adams PD, Afonine P V, Bunkóczi G, et al (2011) The Phenix software for automated determination of 
macromolecular structures. Methods 55:94–106. https://doi.org/10.1016/j.ymeth.2011.07.005 
Aubourg P, Scotto J, Rocchiccioli F, et al (1986) Neonatal adrenoleukodystrophy. J Neurol Neurosurg 
Psychiatry 49:77–86. https://doi.org/10.1136/jnnp.49.1.77 
Babior BM, Kipnes RS, Curnutte JT (1973) Biological defense mechanisms. The production by 
leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 52:741–744. 
https://doi.org/10.1172/JCI107236 
Bade R, Chan HF, Reynisson J (2010) Characteristics of known drug space. Natural products, their 
derivatives and synthetic drugs. Eur J Med Chem 45:5646–5652. 
https://doi.org/10.1016/j.ejmech.2010.09.018 
Badger J (2012) Crystallographic fragment screening. Methods Mol Biol 841:161–177. 
https://doi.org/10.1007/978-1-61779-520-6_7 
Balaram P, Bothner-By AA, Dadok J (1972) Negative nuclear Overhauser effects as probes of 
macromolecular structure. J Am Chem Soc 94:4015–4017. https://doi.org/10.1021/ja00766a063 
Baldridge CW, Gerard RW (1932) The extra respiration of phagocytosis. Am J Physiol Content 103:235–
236. https://doi.org/10.1152/ajplegacy.1932.103.1.235 
Bangi E (2019) A drosophila based cancer drug discovery framework. Adv Exp Med Biol 1167:237–248. 
https://doi.org/10.1007/978-3-030-23629-8_14 
Barbieri R, Luchinat C, Parigi G (2004) Backbone-only protein solution structures with a combination 
of classical and paramagnetism-based constraints: A method that can be scaled to large 
molecules. ChemPhysChem 5:797–806. https://doi.org/10.1002/cphc.200301058 
Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: Physiology and 
pathophysiology. Physiol Rev 87:245–313. https://doi.org/10.1152/physrev.00044.2005 
Bern C, Montgomery SP (2009) An Estimate of the Burden of Chagas Disease in the United States. Clin 
Infect Dis 49:e52–e54. https://doi.org/10.1086/605091 
Bertini I, Luchinat C, Parigi G (2002a) Magnetic susceptibility in paramagnetic NMR. Prog Nucl Magn 
Reson Spectrosc 40:249–273. https://doi.org/10.1016/S0079-6565(02)00002-X 
Bertini I, Luchinat C, Parigi G (2002b) Paramagnetic constraints: An aid for quick solution structure 
determination of paramagnetic metalloproteins. Concepts Magn Reson Part A 14:259–286. 
https://doi.org/10.1002/cmr.10027 
Block K, Gorin Y (2012) Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev 
Cancer 12:627–637. https://doi.org/10.1038/nrc3339 
Bodenhausen G, Ruben DJ (1980) Natural abundance nitrogen-15 NMR by enhanced heteronuclear 
spectroscopy. Chem Phys Lett 69:185–189. https://doi.org/10.1016/0009-2614(80)80041-8 
Bosse R, Illy C, Chelsky D (2002) Clinical Screening Amplified Luminescent Proximity Homogenous 
Assay 
Brini E, Fennell CJ, Fernandez-Serra M, et al (2017) How Water’s Properties Are Encoded in Its 
Molecular Structure and Energies. Chem Rev 117:12385–12414. 
42 
 
https://doi.org/10.1021/acs.chemrev.7b00259 
Brown L-A, Baker A (2008) Shuttles and cycles: transport of proteins into the peroxisome matrix. Mol 
Membr Biol 25:363–375. https://doi.org/10.1080/09687680802130583 
Burch RM, Kyle DJ (1991) Mass Receptor Screening for New Drugs. Pharm Res 8:141–147. 
https://doi.org/10.1023/A:1015819431855 
Bush K (2018) Past and present perspectives on β-lactamases. Antimicrob Agents Chemother 
62:e01076-18. https://doi.org/10.1128/AAC.01076-18 
Carretero M, Solis GM, Petrascheck M (2017) C. elegans as Model for Drug Discovery. Curr Top Med 
Chem 17:2067–2076. https://doi.org/10.2174/1568026617666170131114401 
Chatterjee S, Ganguli BN (1986) Improved screening for β-Lactam antibiotics a sensitive, high-
throughput assay using dd-carboxypeptidase and a novel chromophore-labeled substrate. J 
Antibiot (Tokyo) 39:53–57. https://doi.org/10.7164/antibiotics.39.53 
Clore MG, Iwahara J (2009) Theory, practice, and applications of paramagnetic relaxation 
enhancement for the characterization of transient low-population states of biological 
macromolecules and their complexes. Chem Rev 109:4108–4139. 
https://doi.org/10.1021/cr900033p 
Cooper J (2020) Peroxisome. In: Encycl. Br. https://www.britannica.com/science/peroxisome. 
Accessed 20 May 2020 
Cudic M, Fields G (2009) Extracellular Proteases as Targets for Drug Development. Curr Protein Pept 
Sci 10:297–307. https://doi.org/10.2174/138920309788922207 
Dalvit C, Fogliatto GP, Stewart A, et al (2001) WaterLOGSY as a method for primary NMR screening: 
Practical aspects and range of applicability. J Biomol NMR 21:349–359. 
https://doi.org/10.1023/A:1013302231549 
Dauter Z (2017) Collection of X-ray diffraction data from macromolecular crystals. Methods Mol Biol 
1607:165–184. https://doi.org/10.1007/978-1-4939-7000-1_7 
Dawidowski M, Emmanouilidis L, Kalel VC, et al (2017) Inhibitors of PEX14 disrupt protein import into 
glycosomes and kill Trypanosoma parasites. Science (80- ) 355:1416–1420. 
https://doi.org/10.1126/science.aal1807 
Dawidowski M, Kalel VC, Napolitano V, et al (2020) Structure-Activity Relationship in Pyrazolo[4,3- 
c]pyridines, First Inhibitors of PEX14-PEX5 Protein-Protein Interaction with Trypanocidal Activity. 
J Med Chem 63:847–879. https://doi.org/10.1021/acs.jmedchem.9b01876 
De Duve C, Baudhuin P (1966) Peroxisomes (microbodies and related particles). Physiol Rev 46:323–
357. https://doi.org/10.1152/physrev.1966.46.2.323 
Delaglio F, Grzesiek S, Vuister GW, et al (1995) NMRPipe: A multidimensional spectral processing 
system based on UNIX pipes. J Biomol NMR 6:277–293. https://doi.org/10.1007/BF00197809 
Denis M, Softley CA, Giuntini S, et al (2020) The photo-catalysed thiol-ene reaction: a new tag to yield 
fast, selective and irreversible paramagnetic tagging of proteins. ChemPhysChem 21:863–869. 
https://doi.org/10.1002/cphc.202000071 
Desborough MJR, Keeling DM (2017) The aspirin story - from willow to wonder drug. Br J Haematol 
177:674–683. https://doi.org/10.1111/bjh.14520 
43 
 
East KW, Leith A, Ragavendran A, et al (2019) NMRdock: Lightweight and Modular NMR Processing. 
BioRxiv. https://doi.org/10.1101/679688 
Eder J, Sedrani R, Wiesmann C (2014) The discovery of first-in-class drugs: Origins and evolution. Nat 
Rev Drug Discov 13:577–587. https://doi.org/10.1038/nrd4336 
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr 
Sect D Biol Crystallogr 66:486–501. https://doi.org/10.1107/S0907444910007493 
Erlanson DA, Davis BJ, Jahnke W (2019) Fragment-Based Drug Discovery: Advancing Fragments in the 
Absence of Crystal Structures. Cell Chem Biol 26:9–15. 
https://doi.org/10.1016/j.chembiol.2018.10.001 
European Medicines Agency (2018) CHMP recommends first oral-only treatment for sleeping sickness 
Farrow NA, Muhandiram R, Pascal SM, et al (1994) Backbone Dynamics of a Free and a 
Phosphopeptide-Complexed Src Homology 2 Domain Studied by 15N NMR Relaxation. 
Biochemistry 33:5984–6003. https://doi.org/10.1021/bi00185a040 
Fino R, Byrne R, Softley CA, et al (2020) Introducing the CSP Analyzer: A novel Machine Learning-based 
application for automated analysis of two-dimensional NMR spectra in NMR fragment-based 
screening. Comput Struct Biotechnol J 18:603–611. https://doi.org/10.1016/j.csbj.2020.02.015 
Goldfischer S, Moore CL, Johnson AB, et al (1973) Peroxisomal and Mitochondrial Defects in the 
Cerebro-Hepato-Renal Syndrome. Science (80- ) 182:62–64. 
https://doi.org/10.1126/science.182.4107.62 
Gossert AD, Jahnke W (2016) NMR in drug discovery: A practical guide to identification and validation 
of ligands interacting with biological macromolecules. Prog Nucl Magn Reson Spectrosc 97:82–
125. https://doi.org/10.1016/j.pnmrs.2016.09.001 
Groemping Y, Lapouge K, Smerdon SJ, Rittinger K (2003) Molecular basis of phosphorylation-induced 
activation of the NADPH oxidase. Cell 113:343–355. https://doi.org/10.1016/S0092-
8674(03)00314-3 
Groemping Y, Rittinger K (2005) Activation and assembly of the NADPH oxidase: A structural 
perspective. Biochem J 386:401–416. https://doi.org/10.1042/BJ20041835 
Grzesiek S, Bax A (1992) Improved 3D triple-resonance NMR techniques applied to a 31 kDa protein. J 
Magn Reson 96:432–440. https://doi.org/10.1016/0022-2364(92)90099-S 
Haanstra JR, González-Marcano EB, Gualdrón-López M, Michels PAM (2016) Biogenesis, maintenance 
and dynamics of glycosomes in trypanosomatid parasites. Biochim Biophys Acta - Mol Cell Res 
1863:1038–1048. https://doi.org/10.1016/j.bbamcr.2015.09.015 
Hajduk PJ (2006) SAR by NMR: Putting the pieces together. Mol Interv 6:266–272. 
https://doi.org/10.1124/mi.6.5.8 
Hajduk PJ, Olejniczak ET, Fesik SW (1997) One-dimensional relaxation- and diffusion-edited NMR 
methods for screening compounds that bind to macromolecules. J Am Chem Soc 119:12257–
12261. https://doi.org/10.1021/ja9715962 
Han S, Zaniewski RP, Marr ES, et al (2010) Structural basis for effectiveness of siderophore- conjugated 
monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proc Natl Acad Sci 
U S A 107:22002–22007. https://doi.org/10.1073/pnas.1013092107 
44 
 
Häussinger D, Huang JR, Grzesiek S (2009) DOTA-M8: An extremely rigid, high-affinity lanthanide 
chelating tag for PCS NMR spectroscopy. J Am Chem Soc 131:14761–14767. 
https://doi.org/10.1021/ja903233w 
Ho PL, Lo WU, Chan J, et al (2014) pIMP-PH114 carrying blaIMP-4in a Klebsiella pneumoniae strain is 
closely related to other multidrug-resistant IncA/C2 plasmids. Curr Microbiol 68:227–232. 
https://doi.org/10.1007/s00284-013-0471-x 
Hong DJ, Bae IK, Jang IH, et al (2015) Epidemiology and characteristics of metallo-ß-lactamase-
producing Pseudomonas aeruginosa. Infect Chemother 47:81–97. 
https://doi.org/10.3947/ic.2015.47.2.81 
Hong S, Kim D (2016) Interaction between bound water molecules and local protein structures: A 
statistical analysis of the hydrogen bond structures around bound water molecules. Proteins 
Struct Funct Bioinforma 84:43–51. https://doi.org/10.1002/prot.24953 
Hu MK (1962) Visual Pattern Recognition by Moment Invariants. IRE Trans Inf Theory 8:179–187. 
https://doi.org/10.1109/TIT.1962.1057692 
Huber W, Sinopoli A, Kohler J, et al (2015) Elucidation of direct competition and allosteric modulation 
of small-molecular-weight protein ligands using surface plasmon resonance methods. J Mol 
Recognit 28:480–491. https://doi.org/10.1002/jmr.2465 
Huynh K, Partch CL (2015) Analysis of protein stability and ligand interactions by thermal shift assay. 
Curr Protoc protein Sci 79:28.9.1-28.9.14. https://doi.org/10.1002/0471140864.ps2809s79 
Ikura M, Krinks M, Torchia DA, Bax A (1990) An efficient NMR approach for obtaining sequence-specific 
resonance assignments of larger proteins based on multiple isotopic labeling. FEBS Lett 266:155–
158. https://doi.org/10.1016/0014-5793(90)81528-V 
Iyer GYN, Islam MF, Quastel JH (1961) Biochemical aspects of phagocytosis. Nature 192:535–541. 
https://doi.org/10.1038/192535a0 
Jaskolski M, Dauter Z, Wlodawer A (2014) A brief history of macromolecular crystallography, 
illustrated by a family tree and its Nobel fruits. FEBS J 281:3985–4009. 
https://doi.org/10.1111/febs.12796 
Joss D, Häussinger D (2019) Design and applications of lanthanide chelating tags for pseudocontact 
shift NMR spectroscopy with biomacromolecules. Prog Nucl Magn Reson Spectrosc 114–
115:284–312. https://doi.org/10.1016/j.pnmrs.2019.08.002 
Kabsch W (2010) XDS. Acta Crystallogr Sect D Biol Crystallogr 66:125–132. 
https://doi.org/10.1107/S0907444909047337 
Kalel VC, Emmanouilidis L, Dawidowski M, et al (2017) Inhibitors of glycosomal protein import provide 
new leads against trypanosomiasis. Microb Cell 4:229–232. 
https://doi.org/10.15698/mic2017.07.581 
Katz L, Baltz RH (2016) Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol 
43:155–176. https://doi.org/10.1007/s10295-015-1723-5 
Keeler J, Wothers P (2013) Chemical Structure and Reactivity: An Integrated Approach. OUP Oxford 
Kennedy PGE, Rodgers J (2019) Clinical and neuropathogenetic aspects of human African 
trypanosomiasis. Front Immunol 10:39. https://doi.org/10.3389/fimmu.2019.00039 
45 
 
Krimm I (2015) Le criblage de fragments: Une voie prometteuse pour la conception de médicaments. 
médecine/sciences 31:197–202. https://doi.org/10.1051/medsci/20153102017 
Lacabanne D, Meier BH, Böckmann A (2018) Selective labeling and unlabeling strategies in protein 
solid-state NMR spectroscopy. J Biomol NMR 71:141–150. https://doi.org/10.1007/s10858-017-
0156-z 
Lea WA, Simeonov A (2011) Fluorescence polarization assays in small molecule screening. Expert Opin 
Drug Discov 6:17–32. https://doi.org/10.1517/17460441.2011.537322 
Leto TL, Adams AG, De Mendez I (1994) Assembly of the phagocyte NADPH oxidase: Binding of Src 
homology 3 domains to proline-rich targets. Proc Natl Acad Sci U S A 91:10650–10654. 
https://doi.org/10.1073/pnas.91.22.10650 
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches 
to estimate solubility and permeability in drug discovery and development q settings. Adv Drug 
Deliv Rev 46:3–26. https://doi.org/10.1016/s0169-409x(00)00129-0 
Ludwig C, Guenther UL (2009) Ligand based NMR methods for drug discovery. Front Biosci 14:4565–
4574. https://doi.org/10.2741/3549 
Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR 
spectroscopy. Angew Chemie Int Ed 38:1784–1788. https://doi.org/10.1002/(SICI)1521-
3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q 
McPherson A, Gavira JA (2014) Introduction to protein crystallization. Acta Crystallogr Sect F Struct 
Biol Commun 70:2–20. https://doi.org/10.1107/S2053230X13033141 
Mendes RE, Toleman MA, Ribeiro J, et al (2004) Integron carrying a novel metallo-β-lactamase gene, 
bla IMP-16, and a fused form of aminoglycoside-resistant gene aac(6′)-30/aac(6′)-Ib′: Report 
from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 48:4693–
4702. https://doi.org/10.1128/AAC.48.12.4693-4702.2004 
Michels PAM, Moyersoen J, Krazy H, et al (2005) Peroxisomes, glyoxysomes and glycosomes. Mol 
Membr Biol 22:133–145. https://doi.org/10.1080/09687860400024186 
Müller I (2017) Guidelines for the successful generation of protein-ligand complex crystals. Acta 
Crystallogr Sect D Struct Biol 73:79–92. https://doi.org/10.1107/S2059798316020271 
Neufeld C, Filipp F V, Simon B, et al (2009) Structural basis for competitive interactions of Pex14 with 
the import receptors Pex5 and Pex19. EMBO J 28:745–754. 
https://doi.org/10.1038/emboj.2009.7 
Neuhaus A, Kooshapur H, Wolf J, et al (2014) A novel Pex14 protein-interacting site of human Pex5 is 
critical for matrix protein import into peroxisomes. J Biol Chem 289:437–448. 
https://doi.org/10.1074/jbc.M113.499707 
Neuhaus D, van Mierlo CPM (1992) Measurement of heteronuclear NOE enhancements in biological 
macromolecules. A convenient pulse sequence for use with aqueous solutions. J Magn Reson 
100:221–228. https://doi.org/10.1016/0022-2364(92)90382-H 
Nguyen HH, Park J, Kang S, Kim M (2015) Surface plasmon resonance: A versatile technique for 
biosensor applications. Sensors (Switzerland) 15:10481–10510. 
https://doi.org/10.3390/s150510481 
46 
 
Ni F (1994) Recent developments in transferred NOE methods. Prog Nucl Magn Reson Spectrosc 
26:517–606. https://doi.org/10.1016/0079-6565(94)90000-0 
Nicholls RA, Long F, Murshudov GN (2012) Low-resolution refinement tools in REFMAC5. Acta 
Crystallogr Sect D Biol Crystallogr 68:404–417. https://doi.org/10.1107/S090744491105606X 
Oschkinat H, Griesinger C, Kraulis PJ, et al (1988) Three-dimensional NMR spectroscopy of a protein in 
solution. Nature 332:374–376. https://doi.org/10.1038/332374a0 
Otting G, Wüthrich K (1990) Heteronuclear filters in two-dimensional [1H, 1H]-NMR spectroscopy: 
Combined use with isotope labelling for studies of macromolecular conformation and 
intermolecular interactions. Q Rev Biophys 23:39–96. 
https://doi.org/10.1017/S0033583500005412 
Pardi A (1992) Isotope labelling for NMR studies of biomolecules. Curr Opin Struct Biol 2:832–835. 
https://doi.org/10.1016/0959-440X(92)90107-I 
Parkos CA, Dinauer MC, Jesaitis AJ, et al (1989) Absence of both the 91kD and 22kD subunits of human 
neutrophil cytochrome b in two genetic forms of chronic granulomatous disease. Blood 73:1416–
1420. https://doi.org/10.1182/blood.v73.6.1416.bloodjournal7361416 
Patching SG (2014) Surface plasmon resonance spectroscopy for characterisation of membrane 
protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta - Biomembr 
1838:43–55. https://doi.org/10.1016/j.bbamem.2013.04.028 
Peng C, Frommlet A, Perez M, et al (2016) Fast and Efficient Fragment-Based Lead Generation by Fully 
Automated Processing and Analysis of Ligand-Observed NMR Binding Data. J Med Chem 
59:3303–3310. https://doi.org/10.1021/acs.jmedchem.6b00019 
Pérez-Molina JA, Molina I (2018) Chagas disease. Lancet 391:82–94. https://doi.org/10.1016/S0140-
6736(17)31612-4 
Perrin F (1926) Polarization of light of fluorescence, average life of molecules in the excited state. J 
Phys Radium 
Pinazo M-J, Aldasoro E, Calvo-Cano A, et al (2017) Blood and Tissue Protozoa. In: Infectious Diseases, 
4th edn. Elsevier, pp 1751-1762.e1 
Pintacuda G, John M, Su X-C, Otting G (2007) NMR structure determination of protein-ligand 
complexes by lanthanide labeling. Acc Chem Res 40:206–212. 
https://doi.org/10.1021/ar050087z 
Proudfoot A, Bussiere DE, Lingel A (2017) High-confidence protein-ligand complex modeling by NMR-
guided docking enables early hit optimization. J Am Chem Soc 139:17824–17833. 
https://doi.org/10.1021/jacs.7b07171 
Quie PG, White JG, Holmes B, Good RA (1967) In vitro bactericidal capacity of human 
polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of 
childhood. J Clin Invest 46:668–679. https://doi.org/10.1172/JCI105568 
Radwanska M, Vereecke N, Deleeuw V, et al (2018) Salivarian trypanosomosis: A review of parasites 
involved, their global distribution and their interaction with the innate and adaptive mammalian 
host immune system. Front Immunol 9:2253. https://doi.org/10.3389/fimmu.2018.02253 
Rhee YM, Sorin EJ, Jayachandran G, et al (2004) Simulations of the role of water in the protein-folding 
47 
 
mechanism. Proc Natl Acad Sci U S A 101:6456–6461. https://doi.org/10.1073/pnas.0307898101 
Rinaldelli M, Carlon A, Ravera E, et al (2015) FANTEN: A new web-based interface for the analysis of 
magnetic anisotropy-induced NMR data. J Biomol NMR 61:21–34. 
https://doi.org/10.1007/s10858-014-9877-4 
Rodrigues M, Baptista B, Lopes JA, Sarraguça MC (2018) Pharmaceutical cocrystallization techniques. 
Advances and challenges. Int J Pharm 547:404–420. 
https://doi.org/10.1016/j.ijpharm.2018.06.024 
Rucker SP, Shaka AJ (1989) Broadband homonuclear cross polarization in 2D N.M.R. using DIPSI-2. Mol 
Phys 68:509–517. https://doi.org/10.1080/00268978900102331 
Sakurai T, Kanayama M, Shibata T, et al (2006) Ebselen, a seleno-organic antioxidant, as an 
electrophile. Chem Res Toxicol 19:1196–1204. https://doi.org/10.1021/tx0601105 
Sánchez-Pedregal VM, Reese M, Meiler J, et al (2005) The INPHARMA method: Protein-mediated 
interligand NOEs for pharmacophore mapping. Angew Chemie - Int Ed 44:4172–4175. 
https://doi.org/10.1002/anie.200500503 
Santella G, Docquier JD, Gutkind G, et al (2011) Purification and biochemical characterization of IMP-
13 metallo-β-lactamase. Antimicrob Agents Chemother 55:399–401. 
https://doi.org/10.1128/AAC.00421-10 
Sattler M, Schleucher J, Griesinger C (1999) Heteronuclear multidimensional NMR experiments for the 
structure determination of proteins in solution employing pulsed field gradients. Prog Nucl Magn 
Reson Spectrosc 34:93–158. https://doi.org/10.1016/S0079-6565(98)00025-9 
Schanda P, Brutscher B (2005) Very fast two-dimensional NMR spectroscopy for real-time 
investigation of dynamic events in proteins on the time scale of seconds. J Am Chem Soc 
127:8014–8015. https://doi.org/10.1021/ja051306e 
Schmitz C, Bonvin AMJJ (2011) Protein-protein HADDocking using exclusively pseudocontact shifts. J 
Biomol NMR 50:263–266. https://doi.org/10.1007/s10858-011-9514-4 
Schrader M, Fahimi HD (2008) The peroxisome: Still a mysterious organelle. Histochem Cell Biol 
129:421–440. https://doi.org/10.1007/s00418-008-0396-9 
Schrödinger LLC The PyMOL Molecular Graphics System, Version 1.8 
Smith SME, Min J, Ganesh T, et al (2012) Ebselen and congeners inhibit NADPH oxidase 2-dependent 
superoxide generation by interrupting the binding of regulatory subunits. Chem Biol 19:752–763. 
https://doi.org/10.1016/j.chembiol.2012.04.015 
Softley CA, Bostock MJ, Popowicz GM, Sattler M (2020a) Paramagnetic NMR in drug discovery. J 
Biomol NMR 74:287–309. https://doi.org/10.1007/s10858-020-00322-0 
Softley CA, Zak KM, Bostock MJ, et al (2020b) Structure and molecular recognition mechanism of IMP-
13 metallo-β-lactamase. Antimicrob Agents Chemother 64:e00123-20. 
https://doi.org/https://doi.org/10.1128/AAC.00123-20 
Solbak SMØ, Zang J, Narayanan D, et al (2020) Developing Inhibitors of the p47phox-p22phox Protein-
Protein Interaction by Fragment-Based Drug Discovery. J Med Chem 63:1156–1177. 
https://doi.org/10.1021/acs.jmedchem.9b01492 
Stone E (1763) XXXII. An account of the success of the bark of the willow in the cure of agues. In a 
48 
 
letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. 
Edward Stone, of Chipping-Norton in Oxfordshire. Philos Trans R Soc London 53:195–200. 
https://doi.org/10.1098/rstl.1763.0033 
Studier FW (2005) Protein production by auto-induction in high-density shaking cultures. Protein Expr 
Purif 41:207–234. https://doi.org/10.1016/j.pep.2005.01.016 
Su XC, Man B, Beeren S, et al (2008) A dipicolinic acid tag for rigid lanthanide tagging of proteins and 
paramagnetic NMR spectroscopy. J Am Chem Soc 130:10486–10487. 
https://doi.org/10.1021/ja803741f 
Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–
519. https://doi.org/10.1038/nrd3480 
Tacconelli E, Carrara E, Savoldi A, et al (2017) Global priority list of antibiotic-resistant bacteria to guide 
research, discovery, and development of new antibiotics 
Tooke CL, Hinchliffe P, Bragginton EC, et al (2019) β-Lactamases and β-Lactamase Inhibitors in the 21st 
Century. J Mol Biol 431:3472–3500. https://doi.org/10.1016/j.jmb.2019.04.002 
Ullman EF, Kirakossian H, Singh S, et al (1994) Luminescent oxygen channeling immunoassay: 
Measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A 
91:5426–5430. https://doi.org/10.1073/pnas.91.12.5426 
Valenti D, Neves JF, Cantrelle FX, et al (2019) Set-up and screening of a fragment library targeting the 
14-3-3 protein interface. Medchemcomm 10:1796–1802. https://doi.org/10.1039/c9md00215d 
Van Zundert GCP, Rodrigues JPGLM, Trellet M, et al (2016) The HADDOCK2.2 Web Server: User-
friendly integrative modeling of biomolecular complexes. J Mol Biol 428:720–725. 
https://doi.org/10.1016/j.jmb.2015.09.014 
Vranken WF, Boucher W, Stevens TJ, et al (2005) The CCPN data model for NMR spectroscopy: 
Development of a software pipeline. Proteins Struct Funct Genet 59:687–696. 
https://doi.org/10.1002/prot.20449 
Walter T, Erdmann R (2019) Current Advances in Protein Import into Peroxisomes. Protein J 38:351–
362. https://doi.org/10.1007/s10930-019-09835-6 
Watson JD, Crick FH (1953) The structure of DNA. Cold Spring Harb Symp Quant Biol 18:123–131. 
https://doi.org/10.1101/SQB.1953.018.01.020 
WHO (2020a) Trypanosomiasis, human African (sleeping sickness). In: World Heal. Organ. Fact Sheets. 
https://www.who.int/en/news-room/fact-sheets/detail/trypanosomiasis-human-african-
(sleeping-sickness). Accessed 22 May 2020 
WHO (2020b) Chagas disease (also known as American trypanosomiasis). In: World Heal. Organ. Fact 
Sheets. https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-
trypanosomiasis). Accessed 22 May 2020 
William Orton H, Huber T, Otting G (2020) Paramagpy: software for fitting magnetic susceptibility 
tensors using paramagnetic effects measured in NMR spectra. Magn Reson 1:1–12. 
https://doi.org/10.5194/mr-1-1-2020 
Williamson MP (2013) Using chemical shift perturbation to characterise ligand binding. Prog Nucl 
Magn Reson Spectrosc 73:1–16. https://doi.org/10.1016/j.pnmrs.2013.02.001 
49 
 
Winn MD, Murshudov GN, Papiz MZ (2003) Macromolecular TLS Refinement in REFMAC at Moderate 
Resolutions. Methods Enzymol 374:300–321. https://doi.org/10.1016/S0076-6879(03)74014-2 
Zhao WH, Hu ZQ (2011) IMP-type metallo-β-lactamases in Gram-negative bacilli: Distribution, 
phylogeny, and association with integrons. Crit Rev Microbiol 37:214–226. 
https://doi.org/10.3109/1040841X.2011.559944 
Zheng W, Thorne N, McKew JC (2013) Phenotypic screens as a renewed approach for drug discovery. 
Drug Discov Today 18:1067–1073. https://doi.org/10.1016/j.drudis.2013.07.001 
 
  
50 
 
7. Acknowledgements 
Firstly, I would like to thank my supervisor, and project head Prof. Michael Sattler, for the opportunity 
and support over the past four years, and for upholding and cultivating a sense of scientific excellence 
and collaborative discovery within the group.  
Secondly, to Dr. Grzegorz Popowicz, with whom I worked closely for the duration, my heartfelt thanks. 
The support and guidance along the way was invaluable and your enthusiasm for new and exciting 
projects is infectious and keeps us always on our toes. 
My wonderful AEGIS co-workers, collaborators and friends, the constant scientific and personal 
exchange livened up many a day, and the schools and secondments together were a highlight of my 
doctoral studies. To the PIs and to Eva, thank you for the organisation and stimulating questions and 
input to the projects and for making AEGIS such a success.  
I was lucky enough to have an amazing working environment at HMGU. To all of you, and to those at 
TUM, thank you for your generosity with knowledge and time; with care and support. Particular thanks 
go to Mark Bostock, Krzysztof Zak and Michael Ostertag, and to Astrid for making life in the lab so easy 
with her diligence and ever-present smile. 
And last, but of course not least, to my friends and family, both in Germany and abroad, who cannot 
all be named, for their undying love and support, and simply for being there. In particular, to my 
parents, for 26 years of love, advice and encouragement; to Bex, for the laughs, for reminding me 
what is important in life, and for the many pictures of Max; to Abi, Alice and Joy, for motivation and 
support, and of course to Adam, for spiriting me away to the mountains when I needed a break, I could 
not have done it without you all.
51 
 
8. Appendices 
 
Appendix Details Type 
1 Structure and Molecular Recognition Mechanism of IMP-13 
Metallo-β-Lactamase 
C. A. Softley, M. J. Bostock, K. M. Zak et al. 
Antimicrobial Agents and Chemotherapy 
https://doi.org/10.1128/AAC.00123-20 
 
Publication 
2 Paramagnetic NMR in Drug Discovery 
C. A. Softley, M. J. Bostock et al. 
Journal of Biomolecular NMR 
https://doi.org/10.1007/s10858-020-00322-0  
 
Publication 
3 Deep Learning Model Predicts Water Interaction Sites on the 
Surface of Proteins using Limited-Resolution Data 
J. Zaucha, C. A. Softley et al. 
RSC Chemical Communications (Submitted) 
 
Publication 
(submitted) 
4 Introducing the CSP Analyzer: a Novel Machine Learning-based 
Application for Automated Analysis of two-dimensional NMR 
spectra in NMR Fragment-based Screening 
R. Fino, R. Byrne et al. 
Computation and Structural Biotechnology Journal 
https://doi.org/10.1016/j.csbj.2020.02.015 
 
Publication 
5 The Photocatalysed Thiol‐ene reaction: A New Tag to Yield Fast, 
Selective and Irreversible Paramagnetic Tagging of Proteins 
M. Denis et al.  
ChemPhysChem 
https://doi.org/10.1002/cphc.202000071 
 
Publication 
6 Developing Inhibitors of the p47phox−p22phox Protein−Protein 
Interaction by Fragment-Based Drug Discovery 
S. M. Ø. Solbak et al. 
Journal of Medicinal Chemistry 
https://doi.org/10.1021/acs.jmedchem.9b01492 
 
 
Publication 
 
